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ABSTRACT 
 Renal cell carcinoma (RCC) is one of the ten most common cancers affecting men 
and women in the United States. Clear-cell RCC is the predominant subtype and is 
characterized by genomic instability and genetic heterogeneity. The genome is constantly 
under attack from both endogenous and exogenous stressors. Cells utilize the DNA 
damage response to signal and correct potentially deleterious alterations to the genome. 
However, if these processes are unable to adequately repair damaged DNA, serious 
health issues can arise. Studies in our laboratory have established Jade-1 as a tumor 
suppressor in renal cancer. Jade-1 induces apoptosis, deters proliferation, and inhibits 
oncoproteins AKT1 and β-catenin. pVHL, the major renal tumor suppressor, is able to 
bind and stabilize Jade-1. Furthermore, Jade-1 has known connections to DNA. For 
example, Jade-1 has transcriptional activity and is associated with the histone 
acetyltransferases TIP60 and histone acetyltransferase binding to ORC 1 (HBO1). Jade-1 
also facilitates DNA replication. However, it is unknown if Jade-1 is directly involved in 
any DNA repair processes. Through immunoprecipitation studies we discovered that 
Jade-1 associates with proteins involved in several DNA repair mechanisms, including 
double-strand break (DSB) repair. Genomic instability, as occurs in RCC, is due to 
  ix 
defects in repair of DNA DSBs, making this Jade-1 association particularly relevant to 
renal cancer. Additional co-immunoprecipitation studies confirmed that Jade-1interacts 
with DNA-dependent protein kinase catalytic subunit and DNA damage binding protein 
1, DNA-PKcs and DDB1. We also demonstrated that Jade-1 protein levels increase when 
kidney cells are subjected to a radiomimetic agent that induces DSBs. Furthermore, Jade-
1 co-localizes to damage sites represented by γH2AX. These foci are undergoing active 
non-homologous end-joining repair as revealed by phospho-DNA-PKcs signal. 
 This work provides insight as to how Jade-1, by interacting with DNA damage 
proteins, functions as a tumor suppressor in RCC. Future investigation could explore how 
Jade-1 might regulate DNA repair through a host of its known functional activities.  
Overall, this work bolsters our understanding of molecular underpinnings of RCC and 
highlights Jade-1 as a potential therapeutic target. 
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CHAPTER ONE: INTRODUCTION 
Section One: Renal Cell Carcinoma 
 Renal-cell carcinoma (RCC) is one of the ten most common adult cancers in the 
United States. It is estimated that 73,820 new kidney and renal pelvis cancer cases will 
arise resulting in 14,770 deaths in the US in 2019. More men are affected by this disease 
than women, in both number of new cases (44,120 versus (vs) 29,700) and those that 
succumb to the disease (~8,124 vs 3,397) (Siegel, Miller, & Jemal, 2019), as seen in 
Figure 1. The incidence of kidney and renal pelvis cancer is steadily increasing, while 
deaths have declined over the years. The median age of diagnosis is 64 years and median 
age of death is 71 years. Those who are diagnosed with localized disease have 5-year 
survival rate of approximately 75%. However, around 30% of individuals are diagnosed 
with regional spread or distant disease and, for those individuals whose cancer has 
metastasized, only 12% survive 5 years. Additionally, African Americans and Native 
Americans are more likely to have this disease than whites, Asians, and Hispanics (SRP, 
2018). It is estimated the more than half a million people are currently living with kidney 
cancer in this country. 
 The kidneys are important organs. Nephrons, which are the kidneys’ functional 
units, filter the blood and excrete water-soluble wastes. The kidneys maintain electrolyte 
homeostasis and water balance. Each kidney has about 1 million nephrons, which are 
made up of a bundle of capillaries called the glomerulus, which is surrounded by 
Bowman’s capsule. The other parts that follow are the proximal tubule, loop of Henle, 
the distal tubule, and the collecting duct, where urine is transported to the bladder (Figure 
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2). The proximal tubule epithelial cells are thought to be precursor cells of clear-cell RCC 
(ccRCC). The human kidney-2, or HK-2 cell line, used in the present studies is derived 
from human proximal tubule cells and retains many characteristics of the primary cells. 
HK-2 cells are well-differentiated and express proximal tubule markers such as alkaline 
phosphatase, fibronectin, and acid phosphatase. HK-2 cells are also responsive to stimuli 
that confirm their function as proximal tubule cells (Ryan et al., 1994). 
Subsection One: Symptoms 
Patients with RCC may present with a variety of symptoms. These include blood 
in the urine, a palpable mass in the abdomen, fever or weight loss. RCC may not be easily 
diagnosed as symptoms are often attributed to other illnesses. Therefore, follow up tests 
must be done to determine if a patient has RCC. Exams include ultrasound, computerized 
tomography (CT) scan or magnetic resonance imaging of the abdomen. Individuals with 
RCC may also be asymptomatic until the cancer is advanced. Risk factors for RCC 
include smoking and obesity as well as chronic kidney disease (Lipworth, Tarone, & 
McLaughlin, 2006). Genetic predisposition, particularly mutations in the von Hippel-
Lindau (VHL) gene, also contribute to disease pathogenesis. 
Subsection Two: Categorization 
RCC originates in the tubules of the kidney, and the most common subtype is 
ccRCC. ccRCC accounts for about 80% of  RCC tumors (Motzer et al., 2017). Less 
common RCC types include papillary, chromophobe, and medullary tumors. However, 
all the subtypes are associated with chromosomal abnormalities (see Table 1). Tests are 
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done to diagnose and determine the cancer stage. RCC is categorized into four stages 
depending on whether the tumor is confined to the kidney or if it has spread elsewhere. If 
the tumor is 7 centimeters (cm) or less and is found solely in the kidney it is a Stage I 
tumor. If the tumor is greater than 7 cm, but remains in the kidney is it considered Stage 
II. At Stages III and IV, the cancer has spread (metastasized) to other parts of the body 
either through the lymph nodes, blood vessels, or by local invasion. At Stage III the 
cancer can be any size and have spread to one lymph node or the fatty tissue surrounding 
the kidney. When the tumor has spread beyond the layer of adipose around the organ and 
into the adrenal glands, bone, brain, or multiple lymph nodes, as well as other areas, it is 
defined as a Stage IV tumor (PDQ Adult Treatment Editorial Board, 2002), as seen in 
Figure 3. 
Subsection Three: Treatments 
 Treatment options can differ depending on the cancer stage, tumor grade, and the 
patient’s age and general health. For tumors in Stage I, II, and III surgery is a viable 
option for removing the cancer. Radical nephrectomy is performed if the cancer is 
detected in the inferior vena cava, through which the blood is returning to the heart. 
Partial nephrectomy is done when trying to preserve kidney function, i.e. if the other 
kidney is damaged or has already been removed. If partial or full resection is not possible 
then arterial embolization or other ablative approaches can be performed. Embolization 
interrupts blood flow to the kidney, which prevents the cancer cells from getting the 
oxygen and other nutrients they need for survival. Affected lymph nodes or the adrenal 
gland may also be removed as necessary (Motzer et al., 2017). Active monitoring or 
  
4 
ablative techniques, such as cryoablation, are better options for older patients or those 
with comorbidities that would make surgery too risky. 
 Targeted therapy can also be an effective strategy to slow tumor progression with 
advanced disease. Small molecule drugs or biologics, such as monoclonal antibodies, 
inhibit specific molecules that promote tumor growth. For example, the angiogenic factor 
vascular endothelial growth factor (VEGF) is particularly important in the pathogenesis 
of ccRCC. VEGF inhibitors, such as monoclonal antibodies or small-molecule tyrosine 
kinase inhibitors (TKIs), such as sunitinib and axitinib, are effective in impeding new 
blood vessel formation and inhibiting cancer cell growth. Immunotherapies are also of 
value in the treatment of RCC. Kidney cancer cells are responsive to immune cell activity 
(and factors) and communicate with lymphocytes to hinder their elimination. Interleukin-
2 (IL-2) therapy, which stimulates lymphocyte proliferation to attack cancer cells, had 
been the standard of care for late-stage disease. More recently, immune checkpoint 
inhibitors, such as programmed cell death protein 1 (PD-1) inhibitor nivolumab, have 
become a standard approach to treat ccRCC. Malignant cells can evade death when they 
produce surface antigens, such as PD-ligands, that the T-cell determines as “safe”. 
However, antibodies directed against these surface markers and receptors are being 
developed to allow T-cells to recognize and kill the tumor cells. 
Subsection Four: Molecular and Genetic Characteristics 
As previously mentioned there are different RCC subtypes. The three major ones 
are clear-cell (75%), papillary (type 1 and type 2, 15-20%), and chromophobe RCC (5%) 
(Ricketts et al., 2018). Distinct morphological, genetic, and biological alterations define 
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each of these kidney cancers. ccRCC will be discussed in the following section as most 
patients, even those with hereditary disease, have this type. Advancements in genetic 
sequencing have further confirmed known genes implicated in less prevalent conditions. 
The mesenchymal-epithelial transition (MET) gene is one such example in papillary RCC 
(pRCC). This gene resides on chromosome 7, which is frequently amplified in type 1 
pRCC. The protein encoded is c-MET, a hepatocyte growth factor/scatter growth tyrosine 
kinase receptor that modulates the mammalian target of rapamycin (mTOR) and signal 
transducer and activator of transcription 3 (STAT3) pathways. Another gene involved in 
the pathogenesis of type 1 pRCC is leucine-rich repeat kinase 2 (LRRK2), which is found 
on chromosome 17, and gene copy number is also increased. LRRK2 also acts through 
the same pathways as MET to boost cell replication and survival. It is also known that a 
subset of type 2 papillary RCC has CpG island methylator phenotype (CIMP), which 
denotes global hypermethylation of tumor suppressor genes (Ricketts et al., 2018). The 
fumarate hydratase (FH) gene is one such example that is inactivated by methylation and 
is associated with type 2 pRCC. The loss of enzyme activity permits fumarate 
accumulation, which interferes with degradation of the hypoxia inducible factor alpha 
(HIFα) proteins. Consequently, expression of genes involved in angiogenesis and glucose 
transport is elevated. Additionally, increased fumarate levels prevent degradation of the 
transcriptional activators in the nuclear factor (erythroid-derived-2)-like 2 (NRF2) 
pathway. The nuclear factor (erythroid-derived) like-1 (NRF1) and NRF2 transcription 
factors stimulate an antioxidant response gene expression signature.  
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 Chromophobe RCC (chRCC) accounts for 5% of RCC cases and is associated 
with the familial hereditary disease Birt-Hogg-Dube (BHD) syndrome. In BHD, germline 
mutations occur in the folliculin (FLCN) gene. This gene is reported to influence 
pathways involved in mitochondrial biogenesis and transforming-growth factor beta 
(TGF-β) signaling. In a mouse model of BHD syndrome, when the FCLN gene is lost in 
the proximal tubule region, multiple tumors are formed, and the mTOR and TGF-β 
pathways are active in these cellular masses (Chen et al., 2015). Tumor protein 53 
(TP53), phosphatase and tensin homolog (PTEN), and the mitochondrial DNA (mtDNA) 
gene (MT-ND5) is also frequently mutated in chRCC. Importantly, a region of 
hypermutation is characteristic of chRCC. The telomerase reverse transcriptase (TERT) 
promoter region is distinctly rearranged which increases the expression of the catalytic 
subunit of telomerase and permits genetic aberrations to take place (C. F. Davis et al., 
2014). 
Section Two: ccRCC 
Subsection One: Cell origins and Visual Characteristics 
 ccRCC originates from the renal proximal tubular epithelia and is named as such 
because tumor cells have a clear cytoplasm under light microscopy. The tumor mass is 
also yellowish in appearance due to the accumulation of lipids and glycogen in the 
cytoplasm (Figure 4). Additionally, thin blood vessels surround the tumor and separate it 
into various sections. The tumor can also have regions of necrosis, hemorrhage or cystic 
growth (Oya, 2010). Other distinct cellular morphology, such as eosinophilic cytoplasm, 
usually indicates a more aggressive, higher-grade disease. All of these features are taken 
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into account to definitively diagnose ccRCC since some of these phenotypes can be 
found in other subtypes. 
Subsection Two: Genetic Findings 
Although there is a great deal of tumor heterogeneity in ccRCC, the most 
consistent genetic alterations are found in the von-Hippel Lindau gene. Through genetic 
analysis, it has been determined that the short arm of chromosome 3, where the gene 
resides, is deleted in a majority of individuals affected with RCC. Additionally, this 
gene’s promoter region is hypermethylated in 20% of patients. VHL gene inactivation is 
found in more than half of all tumors, and, VHL is regarded as the major kidney cancer 
tumor suppressor gene. More recent detailed analyses indicate that more than 90% of 
ccRCCs harbor VHL defects. 
Furthermore, information obtained through The Cancer Genome Atlas (TCGA) 
consortium, which analyzed 417 tissue samples, identified unexpected genes that 
influence disease pathogenesis and progression. For example, commonly affected genes 
are involved in chromatin dynamics and structure. Among these are polybromo 1 
(PBRM1), SET domain containing protein 2 (SETD2), and BRCA1-associated protein 1 
(BAP1). All of these are also located on chromosome 3p, which is lost in >90% of all 
samples evaluated (Cancer & Atlas, 2013). These findings suggest that proper epigenetic 
control of gene expression suppresses oncogenesis uniquely in kidney cells. Thus, when 
abnormalities take place, this permits an environment where DNA-related processes can 
be dysregulated and stimulate tumorigenesis. 
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The SETD2 protein is a histone H3 lysine 36 (H3K36) methyltransferase, and 
mutations in this gene allow for down-regulated DNA methylation at non-promoter 
regions. It has been shown that this trimethylation is important for keeping regions in a 
heterochromatic state via DNA methyltransferase 3a (DNMT3A) (Dhayalan et al., 2010). 
Interestingly, H3K36 modifications also have an impact in mismatch repair initiation as 
discovered by Li et al. (S. K. H. Li & Martin, 2016).  
There were other important findings in the TCGA study.  First, a high percentage 
of tumors had arm level loss of chromosome 14q and gain of chromosome 5q, 45% and 
67%, respectively.  Second, the study also reported that found that the 
phosphatidylinositol 3 kinase/AGC family kinase (PI(3)K)/AKT) pathway components 
were mutated and that this an important, potential avenue for therapeutic intervention.  
Subsection Three: Molecular Changes 
The most common molecular changes are due to the gene expression changes that 
occur when mutations take place. For example, due to VHL mutations, hypoxia inducible 
factor 1 alpha (HIF1α) expression is upregulated in ccRCC tumors. This stabilization 
induces expression of the glucose transporter 1 (Glut-1), carbonic anhydrase IX (CA-IX), 
and VEGF genes. DNA promoter hypermethylation is a feature of ccRCC, likely due to 
mutations in the chromatin modifier, SETD2. This characteristic was positively-
correlated with increasing tumor stage and grade (Cancer & Atlas, 2013). Metabolic 
shifts, compatible with the Warburg hypothesis, in which cells switch to anaerobic 
glycolysis for adenosine triphosphate (ATP) generation, are also key features of ccRCC 
tumors. 
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Section Three: VHL Disease and Functions of pVHL 
 Much of what is known about ccRCC derives from studies done in patients with 
VHL disease, a familial hereditary syndrome in which the most malignant clinical 
manifestation is ccRCC. Less than 5% of all diagnosed ccRCC cases are attributed to 
VHL disease. VHL is a tumor suppressor gene, and both alleles must be inactivated to 
contribute to disease. In this autosomal dominant condition, individuals inherit one 
mutant allele from a parent and eventually individual cells have loss of the wild-type 
allele. Once loss of heterozygosity (LOH) occurs, the affected person can develop a 
variety of ailments. The most prevalent tumors that arise are retinal angiomas, central 
nervous system hemangioblastomas, and pheochromocytomas. 
 Discovery of the VHL gene was made by Latif and colleagues in 1993, with the 
use of samples from patients with VHL disease and sporadic ccRCCs (Latif et al., 1993). 
Since then, many follow-up studies have uncovered the function of von Hippel-Lindau 
tumor suppressor protein (pVHL), the protein encoded by VHL. pVHL is most well-
known for its oxygen-sensing function in the cell. It is a key regulator of the HIFα 
subunits, which induce expression of genes important in angiogenesis, cell growth, and 
metabolism (Othon Iliopoulos, 1996). pVHL, in a complex with elongin C, cullin-2 
(cul2) and Ring Box 1 (Rbx1), targets the HIFs for degradation, as it is the ubiquitin 
ligase for these molecules as seen in Figure 5 (Maxwell et al., 1999; Ohh et al., 2000) 
Investigations done in the human renal cancer cell line, 786-O cells, which are VHL-
negative, demonstrate that when wild-type VHL is re-introduced, cells are protected from 
apoptosis (Devarajan et al., 2001; Schoenfeld et al., 2000). In vivo studies done with 786-
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Os stably expressing pVHL show that fewer tumors are formed and that they are smaller 
in size (O Iliopoulos, Kibel, Gray, & Kaelin, 1995). 
Apart from its role in sensing low oxygen conditions, pVHL also plays a role in 
DNA damage response pathways. pVHL was shown to positively influence p53, a key 
regulator in cell cycle progression, apoptosis, and promoter of DNA repair pathways. It 
interacts with p53 and is able to affect p53 phosphorylation at serine (S)15 via ataxia 
telangiectasia-mutated (ATM) kinase. pVHL also promotes p53 transcriptional activity 
on promoter region of p21WAF1/cip1 and Bcl-2 associated X (Bax). Moreover, Roe and 
colleagues found that p53 acetylation at lysine (K) residues 373 and 282 is impacted by 
pVHL (J.-S. Roe & Youn, 2006). Subsequently, this group also found that checkpoint 
kinase 2 (Chk2) is responsible for phosphorylating pVHL, at serine 111, and this is 
important for the ability of pVHL to act on p53. This pVHL post-translational 
modification was also important for cell cycle arrest and apoptosis in RCC4 cells, which 
express mutant phospho-pVHLS111D. The histone acetyltransferases Tat-interactive 
protein 60 (TIP60) and p300 are also able to bind pVHL, and these help support p53 
transcriptional activity in a DNA damage-dependent manner (J. S. Roe et al., 2011). 
Another study found that suppressor of cytokine signal 1 (SOCS1) facilitates pVHL K63 
ubiquitination, a signaling mechanism when damage is present. SOCS1 knockdown 
diminishes this modification on pVHL in kidney cells. Furthermore, decreased pVHL 
K63 ubiquitination also affected signaling of other DNA damage response (DDR) 
proteins such as phosphorylated histone H2AX variant (γH2AX), phosphorylated 
checkpoint kinase 1 (phospho-Chk1), and phospho-ATM. Use of a functional 
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homologous recombination repair (HRR) assay indicated that pVHL influences this 
mechanism, since green fluorescent protein (GFP) detection, indicating repair, was 
decreased two-fold with VHL knockdown (Metcalf et al., 2014). 
Recently, Scanlon et al. reported that VHL-deficient renal cancer cells had 
decreased expression of the homologous recombination (HR) and mismatch repair 
(MMR) genes Fanconi Anemia complementation group D2 (FANCD2), breast cancer 
susceptibility 1(BRCA1), RAD51, Mut L homolog 1 (MLH1), compared to their wild-type 
counterparts. Additionally, this group found less intact DNA via comet assays and 
impaired double-strand break (DSB) repair via homologous recombination in the VHL-
negative cells. These lines were also more sensitive to the poly-ADP-ribose polymerase 
(PARP) inhibitor, olaparib, suggesting that complementary DSB repair pathways are 
enlisted in these cells. Moreover, specific analysis of FANCD2, BRCA1, RAD51, and 
MLH1 in renal clear cell carcinoma samples from TCGA database found a reduction in 
expression levels of these genes in VHL-deficient tumors (Scanlon, Hegan, Sulkowski, & 
Glazer, 2017). 
Research done in the VHL-deficient RCC4 cells exposed to the environmental 
toxin benzo[a]pyrene (BaP) demonstrates that the detoxifying response is impaired. BaP 
is converted to BaP-7,8-diol-9,10 epoxide (BPDE), and this metabolite can form DNA 
adducts, which are repaired by nucleotide excision repair (NER). However, if cells are in 
hypoxic state, or in a condition where this is simulated, there is greater genomic 
instability. Shults et al. showed that absence of VHL diminished the ability to repair DNA 
via the NER mechanism (Schults, Oligschlaeger, Godschalk, Van Schooten, & Chiu, 
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2013). In support of the relationship between pVHL and NER, another group found that 
pVHL mediated RNA polymerase II (RNA Pol II) degradation, and this was important 
for the effective killing of cells with trabectidin, a drug that specifically targets the 
transcription-coupled (TC) NER pathway (Aune et al., 2009). 
 Although some efforts had been made to produce an animal model that 
recapitulates human disease by deleting the VHL gene, none of these showed a ccRCC 
phenotype. However, a research team at Weill Cornell Medical College was able to 
create transgenic model cancer of the kidney (TRACK) mice. Proximal tubule (PT) cells 
were targeted using the type 1-γ-glutamyl transpeptidase (γGT) promoter to drive 
expression of a HIF1α triple mutant, which allows for the constitutive presence of this 
subunit. These rodents exhibited many characteristics similar to that of human ccRCC, 
such as multiple renal cysts, clear-cell carcinomas, and distorted tubules. Importantly, 
these abnormal PT cells also showed increased γH2AX signal compared to normal cells, 
which indicates increased genetic instability (Fu, Wang, Shevchuk, Nanus, & Gudas, 
2011). 
Section Four: Jade-1 
Jade-1 is a kidney-enriched protein with tumor suppressor function. Using a yeast 
two-hybrid approach, our laboratory identified a novel pVHL-interacting protein and 
named it Jade-1. The Jade-1 (gene for apoptosis and differentiation in epithelia) gene 
encodes a 3.6 kilobase (kb) transcript that is translated into the 509 amino acid (aa) 
protein (see Figure 6B). Zhou et al. found that pVHL binds and stabilizes Jade-1 (Zhou et 
al., 2002). Further studies revealed that Jade-1 has pro-apoptotic effects when stably 
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expressed in renal cancer cells and anti-apoptotic effects when it is silenced. 
Additionally, Jade-1 slows cell proliferation and attenuates DNA synthesis, supporting 
tumor suppressor function (Zhou et al., 2005). 
Jade-1 likely influences tissue development as reported by Tzouanacou et al. This 
group found that Jade-1 expression occurs early  in embryogenesis and follows a 
restricted pattern, specifically in regions where pluripotent or tissue-specific progenitor 
populations reside (Tzouanacou, Tweedie, & Wilson, 2003). 
Chitalia et al., in our laboratory, discovered that Jade-1 binds β-catenin, an 
important protein involved in development as well as in cancer pathogenesis. Our 
laboratory also determined that Jade-1 has E3 ubiquitin ligase activity and targets β-
catenin, the canonical Wnt pathway effector, for proteasomal degradation. Interestingly, 
Jade-1 was unable to ubiquitinate a mutated, cancer-causing form of β-catenin, 
suggesting that this evasion may further contribute to disease progression (Chitalia et al., 
2008). Studies conducted on human RCC tissue found that both low Jade-1 and high β-
catenin expression and protein levels correlate to poor prognosis and survival (Lian et al., 
2012). Our analysis of the much larger database, The Cancer Genome Atlas, confirmed 
that reduced Jade-1 message levels are associated with worse outcomes in ccRCC. Zeng 
et al. also demonstrated that Jade-1 binds AKT1 and inhibits AKT1 kinase activity. 
AKT1 is a serine/threonine kinase that is overactive in many cancers. Jade-1 can 
modulate phospho-AKT1 levels; however, it does not do so by facilitating AKT1 
proteasomal degradation (Zeng et al., 2013). Thus, Jade-1 exerts consistently growth 
suppressive biochemical function, and reduced Jade-1 expression correlates with worse 
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clinical outcomes in ccRCC. These findings indicate that Jade-1 is a true renal tumor 
suppressor. 
Furthermore, Jade-1 localization in different cellular compartments suggests its 
multi-functional roles within the cell. Jade-1 contains one canonical plant homeodomain 
(PHD) finger (aa 203-253) and one non-canonical extended PHD (aa 257-371)(see Figure 
6A), both of which are zinc-binding motifs. Proteins containing these domains are usually 
found in the nucleus and are known as transcriptional co-regulators or are included in 
chromatin-modifying complexes. PHD fingers, such as the one in p300, interact with 
nucleosomal histones in an acetylation-independent manner (Ragvin et al., 2004). Our lab 
reported that Jade-1 is found mainly in the nucleus and has transcriptional activity via its 
PHD domains. This study also identified Jade-1 as a component of the TIP60 histone 
acetyltransferase (HAT) complex/TIP60 binding partner, with specific histone H4-
modifying ability (Panchenko, Zhou, & Cohen, 2004). Additionally, Jade-1 strongly 
regulates histone H4 acetylation through its association with the histone acetyltransferase 
binding to ORC 1 (HBO1), which is homologous to TIP60. Foy et al. demonstrated that 
the Jade-1 N-terminus, C-terminus, and PHD zinc fingers, in conjunction with HBO1, 
were critical for increasing global H4 histone acetylation (Foy et al., 2008).  
The HBO1-Jade-1 complex is involved in kidney cell regeneration after ischemic 
reperfusion injury in mice (Havasi et al., 2013). Recently, Siriwardana et al. 
demonstrated that Jade-1 and HBO1 localize to the nucleus in the G1 and G2 phases of 
the cell cycle and, during mitosis, they are detached from chromatin (Siriwardana, Meyer, 
Havasi, Dominguez, & Panchenko, 2014). Moreover, Jade-1 and HBO1 are important for 
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DNA replication. Miotto and Struhl showed that histone H4 acetylation via these 
molecules is important for minichromosome maintenance (MCM) complex loading at 
DNA replication origins (Miotto & Struhl, 2010). 
Jade-1 mRNA and protein levels increase in the presence of double-strand break 
damage in breast cancer cells. Jade-1 induction was dependent on the ATM kinase and 
BRCA1-two critical effectors in the DNA damage response pathway. Histone H4 
acetylation was also modulated as a consequence of DSB damage, supporting a role for 
Jade-1 in this process (Wan et al., 2013). 
Section Five: DNA Repair 
DNA lesions occur constantly within our cells from either intrinsic processes or 
exogenous agents, such as reactive oxygen species (ROS), gamma rays, ultraviolet (UV) 
light, or chemotherapeutic drugs. Although not all genetic insults are detrimental to an 
organism, some lead to serious consequences. Fortunately, the DNA damage response 
system exists to detect the corrupted DNA, initiate cell signaling of this event, and repair 
the damage via different proteins and multi-subunit complexes (Mallette, Gaumont-
Leclerc, & Ferbeyre, 2007). When a cell fails to recognize and repair DNA damage, this 
can lead to its death or its abnormal survival and dysregulation of a variety of cellular 
processes. Not surprisingly, genetic changes that affect molecules involved in DNA 
damage response give rise to cancer. 
Two major signaling pathways are activated depending on the type of damage: 
ATM and ataxia telangiectasia and Rad3-related (ATR). Double- and single-strand 
breaks activate phosphatidylinositol 3 kinase-like kinases (PIKKs), ATM and ATR, 
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respectively. ATM phosphorylates a number of molecules involved in downstream 
signaling and eventual repair including Chk2 (Kitagawa & Kastan, 2005; Kurz & Lees-
Miller, 2004; Matsuoka et al., 2000; Pabla, Huang, Mi, Daniel, & Dong, 2008). ATR is 
activated after ATM activation and phosphorylates Chk1 (Flynn & Zou, 2011; Myers & 
Cortez, 2006). Additionally, the cell cycle stage also determines how double-strand 
breaks are resolved. There are two main double-strand break repair pathways: 
homologous recombination and non-homologous end-joining (NHEJ). 
Homologous recombination ensues if there is a template strand available, such as 
during or post DNA replication, while non-homologous end-joining proceeds when there 
is a not readily available DNA strand. When DSBs occur, proteins must come to stabilize 
the broken strands. In NHEJ, Ku proteins sense and bind the DNA and recruit DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) to form the holoenzyme, DNA-
PK (Dvir, Peterson, Knuth, Lu, & Dynan, 1992; Gottlieb & Jackson, 1993). DNA-PK, 
another PIKK family member, is activated and it is able to phosphorylate itself as well as 
other NHEJ factors (Uematsu et al., 2007). DNA processing and ligation is executed by 
Artemis, DNA ligase IV-X-ray repair cross-complementing protein 4 (XRCC4), and 
XRCC4-like factor (XLF)(Ma, Pannicke, Schwarz, & Lieber, 2002). This protein 
assembly dissociates from DNA after repair is complete (A. J. Davis, Chen, & Chen, 
2014), as seen in Figure 7. During HR, the Mre11, Rad50, and Nbs1 (MRN) complex 
binds broken DNA ends and enlists proteins for strand invasion, branch migration, and 
resolution of Holliday junctions (Jasin & Rothstein, 2013)(Figure 8). 
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DNA-PKcs was first isolated from HeLa cells as a 300 kilodalton (kDa) enzyme. 
It demonstrates phosphorylating activity, specifically in the presence of double-stranded 
DNA, and targets key proteins such as p53, the Ku70/Ku80 (Ku) antigen, RNA pol II, 
and the Sp1 transcription factor. Additionally, autophosphorylation within its catalytic 
component eliminates its modification activity (Carter, Vancurová, Sun, Lou, & DeLeon, 
1990; Chan & Lees-Miller, 1996). Lees-Miller and colleagues determined that DNA-PK 
was a serine/threonine kinase localized to the nucleus. DNA-PK is also a protein complex 
comprising the Ku heterodimeric antigen and a 350 kDa catalytic subunit termed DNA-
PKcs, and the holoenzyme binds DNA ends (Gottlieb & Jackson, 1993). Song et al. 
subsequently found that DNA-PKcs was a much larger protein, approximately 460 kDa 
that had breakdown products at molecular weights ~240, 150, and 120 kDa. DNA-PKcs 
is cleaved by the protease, CPP32, when dissociated from DNA (Song et al., 1996). The 
XRCC7 gene that encodes DNA-PKcs is located on the long arm of chromosome 8 and is 
formed from at least nine exons (Sipley et al., 1995). The complete coding sequence of 
XRCC7 revealed that DNA-PKcs is comprised of more than 4,000 amino acid residues 
and the carboxy terminus had a consensus DXXXXN and aspartic acid-phenylalanine 
glycine (DFG) motifs, like other members of the PI3K superfamily. These proteins are 
commonly known to modify inositol phospholipids, which can impact signaling 
pathways. However, DNA-PKcs does not phosphorylate lipids, only proteins (Hartley et 
al., 1995). There are several known phosphorylation sites on the catalytic portion of 
DNA-PKcs, many of which are located centrally in the protein.  
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Variable diversity and joining, or V(D)J, recombination, which takes places in 
lymphoid cells, is also another critical process that requires DNA-PK. This allows the 
cells to create variable regions on immunoglobulin and T cell receptor genes for diverse 
antigen recognition targeting (Hartley et al., 1995). Blunt et al. determined that mouse 
severe combined immunodeficiency (scid) SCGR11 or Chinese hamster ovary V3 cells, 
which are radiosensitive and have defects in DSB repair/rejoining processes, lack DNA-
PKcs activity. However, when these cell extracts are mixed with the purified catalytic 
subunit there is restoration of phosphorylation activity (Bosma & Carroll, 1991). To 
further support this, with introduction of the X-ray repair cross-complementing group 7 
(XRCC7) gene via yeast artificial chromosomes into complement ionizing radiation (IR) 
group 7 defective cells, they were no longer radiosensitive (Blunt et al., 1995). 
More recent studies have shown that DNA-PKcs and AGC family kinase alpha 
isoform (AKT1) are connected during DNA damage. AKT1 is another serine/threonine 
kinase and known as a pro-tumorigenic enzyme that impacts cell metabolism and cell 
survival. Early studies by Feng and colleagues demonstrated that AKT1 and DNA-PK 
co-localized at the plasma membrane. They also found that DNA-PK phosphorylated 
AKT1 at serine 473 (S473) after insulin stimulation (Feng, 2004). Subsequent work 
revealed that AKT1 is fully activated specifically by DNA-PKcs at S473 in the presence 
of ionizing radiation in the nucleus. AKT1 phosphorylation levels correlated with number 
of γH2AX foci in cells exposed to 1-10 gray (Gy) IR. However at higher IR doses (30 
Gy) there were lower levels of phospho-AKT1. This indicated that at low DSB damage 
levels cell survival dominated over cell death. Additionally, similar to DNA-PKcs 
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deficient cells, AKT1-knockout MEFs displayed radiosensitivity- there was greater death 
in the absence of AKT1 compared to wt or AKT2/AKT3 knockout cells. 
S473 modification was also linked to transcriptional regulation of genes involved 
in the DNA damage response pathway such as p21WAF1/cip1. Both mRNA and protein 
expression p21WAF1/cip1 increased when AKT1 was phosphorylated, which led to a 
diminished apoptotic response in vivo and in vitro (Bozulic, Surucu, Hynx, & Hemmings, 
2008). Conversely, AKT1 also has kinase activity toward DNA-PKcs. Toulany et al. 
showed that AKT1 binds DNA-PKcs at its carboxy terminal, kinase domain and that 
AKT1 has an active role in the NHEJ repair mechanism. AKT1 phosphorylation affects 
DNA-PKcs binding to the Ku heterodimer and its localization to DNA damage sites. 
Additionally, AKT1 is able to influence levels of serine 2056 on DNA-PKcs, which is a 
known autophosphorylation modification necessary for proper NHEJ advancement 
(Toulany et al., 2012). Overall, DNA-PK is most well-known for its role in DNA repair. 
However, it is also involved in the cell cycle progression and apoptosis through the DNA 
damage response pathway. 
Moreover, other types of damage, such as pyrimidine dimerization or nucleotide 
mismatches, initiate distinct repair processes. Nucleotide mismatches can be resolved by 
either nucleotide excision repair or mismatch repair. There are two subpathways in NER: 
transcription-coupled NER (TC-NER) or global genome NER (GG-NER) (Figure 9). 
During transcription-coupled repair, RNA polymerase II is stalled when it encounters 
damage on the template strand. When this occurs RNA pol II interacts with a complex 
containing Cockayne syndrome B (CSB) which then allows Cockayne syndrome A 
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(CSA) to bind at the DNA lesion (Groisman et al., 2003). CSA, in conjunction with DNA 
damage-binding protein 1 (DDB1), localizes to the site and recruits repair proteins. In 
GG-NER, the xeroderma pigmentosum complementation group C (XPC) protein and the 
UV-DDB complex, composed of DDB1 and DNA damage-binding protein 2 (DDB2), 
recognize the UV light-mediated lesion, in a non-transcribed region of the genome 
(Hwang, Toering, Francke, & Chu, 1998). This stimulates a repair process that is also 
intrinsic to TC-NER. DDB2 is able to increase DDB1’s localization to the nucleus. 
DDB1 and DDB2 are also components of a ubiquitin ligase complex that promotes the 
degradation of proteins related to DNA repair, replication, and transcription, such as 
histones or cell cycle regulators. DDB1 serves as the adaptor protein, which associates 
with the E3 ubiquitin ligase cullin4A (Cul-4A) (Shiyanov, Nag, & Raychaudhuri, 1999). 
DDB1 is important for the turnover of cyclin-dependent kinase (CDK) inhibitor p27Kip1 
after low doses of UV irradiation (Iovine, Iannella, & Bevilacqua, 2011). p27Kip1 is 
important for the transition from G1 to S phase in the cell cycle and inhibits cell 
proliferation. DDB2 is targeted so that XPC can be recruited to the damage, thus allowing 
for effective NER to proceed. Moreover, the UV-DDB complex preferentially repairs 
cyclobutane pyrimidine dimers (CPDs) over 6-4 pyrimidone photoproducts (6-4PP) (J. Li 
et al., 2006).  
A recent study by Matsunuma and colleagues found that DDB2 can also be part of 
the degradation complex with DDB1 to target HBO1. After UV irradiation, HBO1 is first 
phosphorylated by ATM/ATR and subsequently ubiquitinated by DDB1-DDB2-Cul4A-
RING (Rbx1/Roc1) ligase, CRLDDB2. Consequently, HBO1 turnover disrupts histone H3 
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lysine 14 (H3K14) acetylation and prevents cell cycle progression (Matsunuma et al., 
2016). Another study, by the same group, found that HBO1 was found at CPDs, where it 
is phosphorylated by ATR. At UV-induced damage sites, HBO1 allows XPC recruitment 
and histone H3 and H4 modification. This facilitates DNA unwinding from nucleosomes 
and permits downstream repair processing. Acetyltransferase activity is crucial as DNA is 
usually found in a compact state and damage sites may be inaccessible to repair factors. 
To overcome this barrier, ATP-dependent chromatin modifiers can act on the DNA to 
loosen the tight structure. ATP-dependent chromatin remodeling factor (ACF1) and 
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5 (SNF2H) 
are two such enzymes that were also found at the UV-irradiated sites. The presence of 
these proteins was dependent on HBO1 and DDB2. As a result, XPC accumulated at 
CPDs (Niida et al., 2017). To complete the DNA repair process for both NER pathways, 
the transcription initiation factor IIH (TFIIH) complex accesses the damage site. 
Xeroderma pigmentosum complementation group G (XPG), a structure-specific 
endonuclease, joins the pre-incision complex primed to act on the DNA. However, this 
does not immediately occur as the damage must be verified by other factors. TFIIH must 
unwind the DNA through its helicase subunit XPD and gets help from XPB and XPA. 
XPA binds single-stranded, chemically-altered nucleotides and confirms the existence of 
the lesion. Once replication protein A (RPA) coats the undamaged strand this allows 
XPF-ERCC1 and XPG to excise the DNA at the 5’ and 3’ ends, respectively. In the final 
steps of NER, gap-filling DNA synthesis initiates via proliferating cell nuclear antigen 
(PCNA). Then, different DNA polymerases and ligases are recruited depending on 
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whether the cells are actively replicating or not (Marteijn, Lans, Vermeulen, & 
Hoeijmakers, 2014).  
In the case of MMR, this system is active when there are base mismatches or 
insertion/deletion loops (IDLs) that happen during S phase or heteroduplex mismatches 
after homologous recombination. In addition, this mechanism can also correct when there 
is deamination of 5-methylcytosine, which produces a thymine and subsequent G-T 
mispair. MutS homolog 2 (MSH2) is the principal component for recognizing different 
kinds of damage. MSH2 associates with either MutS homolog 6 (MSH6) or MutS 
homolog 3 (MSH3), creating either MutSα or MutSβ heterodimer, respectively (Acharya 
et al., 1996). These complexes are initially found in the cytoplasm and translocate to the 
nucleus to act on the potential mutation (Christmann & Kaina, 2000). The MutS complex 
requires ATP which creates a conformational change to form a closed clamp around the 
DNA aberration. The clamp can slide in either direction and then exonuclease I (ExoI) 
comes in to cut the newly-reproduced daughter strand. Once this is corrected the DNA is 
reproduced by native DNA polymerases as shown in Figure 10. A study done by Wang et 
al. showed that when cells are treated with the DNA methylating agent, N-methyl-N’-
nitro-nitrosoguanidine (MNNG), to create G-T mismatches, MSH2 interacted with ATR 
to stimulate a cell cycle checkpoint pathway and attenuate DNA replication. ATR then 
phosphorylated Chk1 and structural maintenance of chromosomes protein 1 (SMC1) 
(Wang & Qin, 2003). As with other DNA repair factors, mutations in MMR genes 
contribute to cancer susceptibility and familial cancer syndromes. For example, the gene 
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encoding MSH2, hMSH2, is frequently mutated in hereditary nonpolyposis colon cancer 
(HNPCC).  
  Overall, the DNA damage response is an intricate and highly-regulated process. 
Several factors have different functions when genetic stress occurs, and epigenetic or 
post-translational mechanisms play a critical role in controlling DDR. Chromatin 
modifiers, such as histone acetyltransferases, allow access to damaged DNA while 
kinases and ubiquitin ligases can target proteins involved in activating or recruiting repair 
factors, for example. 
Section Six: Hypothesis 
Initially, we hypothesized that identifying Jade-1 binding partners would reveal 
additional functional pathways in which Jade-1 operates as a renal tumor suppressor. To 
accomplish this, we used an unbiased approach to immunoprecipitate Jade-1 and co-
immunoprecipitate its candidate interactors. After our preliminary mass spectrometry and 
IPA analysis, we hypothesized that Jade-1 directly interacts with key repair proteins, 
specifically DNA-PKcs and DDB1, to regulate, NHEJ and NER, respectively. Jade-1 
may negatively regulate NHEJ repair by ubiquitinating or inhibiting phosphorylation of 
DNA-PKcs thus favoring HR and leading to increased genome stability due to more 
accurate repair. Importantly, this would diminish chromosomal instability that 
characterizes ccRCC and would deter kidney cancer progression. To validate our 
hypothesis we performed biochemical studies, including co-immunoprecipitations of 
transfected and endogenous proteins, immunofluorescence microscopy, and sensitivity 
assays with relevant kidney cells subjected to DNA damage. 
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Section Seven: Figures 
1
 
Figure 1. Top ten cancers in the US showing estimated new cases and deaths by sex, 2019. 
 (Siegel et al., 2019) 
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2A 
 
2B 
 
Figure 2. Simple depiction of the anatomy of kidney and nephron. 
A) A sectional view of the kidney to show main features. The kidney is composed of millions of filtering units 
called nephrons. B) Depiction of the nephron, the basic functional unit of the kidney (Lote, 2012). 
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Table 1. Types of sporadic RCC and the chromosomal abnormalities associated with each subtype (Rini & 
Campbell, 2009). 
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3
 
Figure 3. Stages of RCC along with 5 year survival rates. 
Staging of RCC takes into consideration several factors including tumor size, if it is located within the kidney 
area, and if it has metastasized (Cohen & McGovern, 2005). 
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4A           4B 
              
Figure 4. Gross view and tissue section of ccRCC. 
A) Typical gross visualization of a kidney with ccRCC (upper half of the organ). It usually yellow in appearance 
due to lipid droplets and glycogen in the cytoplasm. B) Tissue section of high grade ccRCC (Oya, 2010). 
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5A      5B 
  
Figure 5. The regulation of pVHL on HIFs in normoxic conditions. 
A) When wild-type pVHL is present in normoxia, the pVHL α domain binds Elongin C of the ubiquitin ligase 
complex while the pVHL β domain binds the HIFα transcription factor when it is hydroxylated by prolyl 
hydroxylase domain enzymes in normoxic conditions. The pVHL-HIFα interaction leads to HIFα ubiquitination 
in normoxia. HIFα is then targeted to the 26S proteasome for degradation. B) When mutant pVHL arises or 
pVHL is absent altogether, even in normal oxygen levels, this regulation on the HIFα transcription factors is 
lost. HIFα is stabilized, dimerizes with HIF1β, and this complex activates transcription of many genes that help 
adapt to the “low oxygen” environment, such as Vegf and Glut1 (Nyhan, O’Sullivan, & McKenna, 2008). 
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Figure 6. Jade-1 schematic and cDNA clone and protein sequence. 
A) Simple diagram demonstrating main domains of Jade-1. The PEST domain is a degradation susceptibility 
region (sequence rich in proline, glutamic acid, serine, and threonine) and two PHD zinc finger motifs 
(underlined). B) The cDNA clone sequence, comprised of 3,570 nucleotides, includes the 5’ and 3’ untranslated 
regions. Candidate post-translational modifications are enclosed in the translated sequence (Zhou et al., 2002). 
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7
 
Figure 7. Diagram of NHEJ. 
NHEJ is activated during any phase of the cell cycle and is a considered a more error prone process since this 
mechanism does not utilize a homologous DNA sequence to repair the DNA. In NHEJ, the Ku heterodimer first 
binds the broken DNA ends. DNA-PKcs is then recruited to form the DNA-PK complex. This tethers the ends 
together to protect them from inappropriate end processing. Artemis, a 5’-3’ exonuclease, is then recruited for 
end processing. XRCC4 (X-ray cross complementing protein 4) and DNA Ligase IV complex ligates the ends 
(Roth, 2003). 
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Figure 8. Diagram of HR. 
DSB repair mediated via HR requires several proteins in this multi-step process. The MRN complex and CtBP-
interacting protein (CtIP) both interact with BRCA1 to permit 5’ to 3’ resection of the DNA ends. ATM is also 
activated as the MRN complex binds DNA. RPA binds to the single-stranded DNA and is phosphorylated. 
Rad52 protects DNA ends from exonuclease activity, and Rad51 nucleoprotein filaments form on the 3’-DNA 
overhangs. Rad52 interacts with Rad51 and this promotes DNA homology search and strand invasion. DNA 
polymerases extend single-stranded DNA which results in branch migration. These crossovers, or Holliday 
junctions, are resolved to complete repair (Khanna & Jackson, 2001). 
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Figure 9. Diagram of NER. 
Bulky DNA adducts are formed through a variety of ways that are repaired by NER. In transcription-coupled 
repair, damage is indirectly recognized by the RNA Pol II that becomes stalled during transcription elongation 
at the damage site. ERCC6 (CSB) interacts with RNA Pol II. Then, ERCC8 (CSA) forms a complex with CSB. 
DDB1 binds CSA which activates DNA repair. In the global genome repair subpathway, lesions are bound by 
the DDB complex containing DDB1 and DDB2 (XPE) which stimulate XPC binding. In both of these pathways, 
CRL4-DDB1 ubiquitin ligase complex forms the main damage sensor that probes the DNA for damage. XPC 
can bind different DNA structures that cause helix distortions. The NER machinery is recruited beginning with 
TFIIH (transcription initiation factor IIH) complex XPB (ERCC3) and XPD (ERCC2) are helicases in the 
complex that unwind the DNA further to the site of damage. CRL4-DDB1 complex ubiquitinates substrates such 
as histones or DDB2 to regulate this process. Other factors are involved in the incision, resynthesis and ligation 
of DNA to repair the damage. XPG (ERCC5) is a structure specific endonuclease. XPD verifies the existence of 
lesions (XPA and XPB help). XPA recruits structure specific endonuclease XPF (ERCC4). ERCC1 incises 5’ to 
the lesion. XPG is activated and cuts 3’ to the lesion (point of no return, excision has taken place). RPA binds 
undamaged DNA strand and RPA is thought to initiate ATR-mediated signaling. The lesion is excised, which 
leaves a 22-30 nt gap. Trimeric proliferating cell nuclear antigen (PCNA) is loaded and recruits DNA 
polymerase δ or κ, for gap filling. The final nick is sealed by DNA ligase I or III (Subba Rao, 2007). 
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Figure 10. Diagram of MMR. 
The MSH2–MSH6 (MutSα) complex recognizes base pair (bp) mismatches and 1-bp insertion/deletion loops 
(IDLs), and the MSH2–MSH3 (MutSβ) complex recognizes 1-bp IDLs and 2–4-bp IDLs. The interaction of 
MLH1–PMS2 (MutLα) activates downstream repair machinery that facilitate the excision, resynthesis, and 
ligation of the DNA strand carrying the aberration. The nature of these later repair steps and the factors 
involved are less well understood. However, Exo1, a 5′→3′ exonuclease, and PCNA are also known to bind to 
MSH2, MSH3 and MLH1 in yeast and mammalian cells. It has been suggested that the interaction with PCNA 
links MMR and DNA replication (Wei, Kucherlapati, & Edelmann, 2002). 
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CHAPTER TWO: MATERIALS AND METHODS 
Cell culture 
Human embryonic kidney 293T (HEK 293T) cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM, Fisher Scientific, MT10017CV) supplemented with 
1% penicillin-streptomycin (Corning, 30-002-CI) and 10% fetal bovine serum (Sigma-
Aldrich, F2442). Adult immortalized human kidney HK-2 cells were also grown in 
complete DMEM, and stable lines were maintained in 2 µg/mL puromycin (Mirus Bio, 
5940). The renal cell carcinoma cell line 786-O and 786-O clonal cell lines stably 
transfected with either pRC-hemagglutinin (HA), pRC-HA-VHL, were grown in Roswell 
Park Memorial Institute (RPMI) 1640 (Corning, MT10040CV). All cell lines were grown 
in a 37°C incubator with 5% CO2 levels in a Forma Scientific water-jacketed incubator. 
 
Constructs 
The Jade-1 5’ untranslated region and coding sequence were cut from pB42AD 
with Not I and Xho I and subcloned into Not I and Sal I cut pFLAG-CMV2 (Sigma-
Aldrich, E7033). The 293T cells were transfected using Lipofectamine 2000 (Life 
Technologies, 11668-027) or TransIT-LT1 (Mirus Bio, MIR2305) transfection reagent 
according to the manufacturer’s instructions. Myc-Jade-1 and myc-β-catenin was cloned 
into pCS2+ expression vector, as previously described (Foy, 2008*). pcDNA3-Flag 
DDB1 was purchased from Addgene (#19918). 
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DNA damage treatments included NCS (Sigma, N9162); Camptothecin (Sigma, C9911); 
SN-38, generously provided by Dr. Ajit Bharti; doxorubicin (Selleckchem, S1208); 
gamma irradiation. HK-2 (or HEK 293T) cells were seeded (225,000 or 450,000 cells) on 
coverslips in 35 mm dishes with 1.5 mLs of medium. The next day, cells were subjected 
to 4 Gray gamma (ionizing) irradiation with a cesium-137 irradiator. The cells were 
either processed for immunofluorescence 1 hour after irradiation or allowed to recover 
from this treatment for the following time points: 2, 4, 8, or 24 hours. 
 
Antibodies 
To generate Jade-1 antisera, 2 New Zealand white rabbits were injected with the 
same C-terminal 20 residue Jade-1 peptide amino terminally linked to keyhole limpet 
hemocyanin (Alpha Diagnostics International, San Antonio, Texas). Additional 
antibodies included FLAG M2 mouse mAb, Sigma-Aldrich, F3165; Mouse IgG-Agarose 
beads, Sigma-Aldrich, A0919; β-catenin mouse mAb, BD Transduction Laboratories, 
610153; β-actin (8H10D10) mouse mAb, Cell Signaling Technologies, 3700; Horse 
radish peroxidase (HRP)-linked anti-rabbit and goat anti-mouse IgG, Bio-Rad, 170-6515 
and170-6516, respectively. DNA damage-related antibodies used included γH2AX  
(Ser139), clone JBW301 mouse mAb, Millipore, 05-636; DNA-PKcs Ab-1 (Clone 18-2) 
mouse mAb, Fisher Scientific, MS369P0; DNA-PKcs phospho-S2056 rabbit mAb, 
Abcam, 124918; Ku70 mouse mAb Abcam, 3114. 
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Transfection 
Cells were seeded the day before transfection (to at least 50% confluence for 
transfection). First, reactions were set up in 1.5 mL microcentrifuge tubes with Gibco 
Opti-MEM (volume varied depending on culture vessel used).  Next, DNA was added to 
tubes and mixed by inverting tube 3 times. DNA amount also varied depending on the 
plate used for seeding. For 6-well plates 1 µg of DNA was used, 2 µg for 60 mm dish, 5 
µg for 100 mm dish and 12 µg for 150 mm dish. Mirus Bio LT1 transfection reagent was 
then added to the mixture and mixed by inverting 3 times. The reagent was used at ratio 
of 1 µg DNA: 3 µl reagent. The reaction mixture was incubated for 20 minutes. Lastly, 
the reaction was added drop-wise into the respective well/plate.  Cells were collected 24 
or 48 hours later and prepared for Western blot. 
 
Cell lysate preparation 
Cold cell lysis buffer was prepared as follows: 1X TBS (50 mM Tris pH 7.4, 150 
mM NaCl), plus 3 mM EDTA and 1% NP-40. Protease inhibitor cocktail solution (100x, 
Thermo Scientific Cat. No.8866), 10 mM NaF, 1 mM Na3OV4,∙ 2H2O, 1 mM DTT, and 1 
mM PMSF were added just before lysis. Cells were seeded the day before transfection or 
treatment. If transfection was performed, cell lysates were collected 24 or 48 hours later. 
Medium was removed from plates, and cells were washed with cold 1X PBS. Lysis 
buffer was added directly to cells; volume added depended on cell type and confluence. 
Cells were incubated with lysis buffer on ice for 5 minutes, then scraped into 1.5 mL 
microcentrifuge tubes. Cells were lysed on ice for 10 minutes, with quick vortex every 3 
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minutes. The extract was centrifuged for 15 minutes at 13,000 rpm in a cold centrifuge. 
Supernatants were transferred to a new microcentrifuge tube and were either stored at -
80°C or prepared immediately for Western blot analysis. 
 
Bradford protein assay and sample preparation 
A 1X solution of Bio-Rad Protein Assay Dye Reagent Concentrate was made 
from 5X stock (Bio-Rad Cat. No. 50000006). One mL of 1X reagent was added to 1.5 
mL microcentrifuge tubes and 2 µl cell lysate was mixed in. Then 900 µl of sample was 
transferred to a cuvette to measure the absorption by a spectrophotometer at 595 nm.  A 
standard curve was used to estimate the protein concentration. An amount of 6X Laemmli 
sample buffer was added to appropriate lysate volume and samples were boiled at 95°C 
for 5 minutes. Samples were spun down to bring down condensation, tubes were tapped 
quickly, and then spun down again for short time prior to gel loading. Samples were 
stored at -20°C if they were going to be used within 10 days. For long-term storage, 
samples were put in -80°C freezer. 
 
Silver stain 
Samples were run on 7.5% sodium dodecyl sulphate (SDS) polyacrylamide gels. 
After electrophoresis, the gel for silver staining was washed with double-distilled water 
in a clean container. The gel was fixed with solution A (50% methanol/10% acetic acid) 
for 30 minutes on platform and removed. Next, fixing solution B (5% methanol/7% 
acetic acid) was added for 1 hour (hr). During this time, 10% glutaraldehyde was made 
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and added once solution B was done incubating for half an hour. The solution was 
removed and the gel was washed with double distilled water five times for 15 minutes 
each time on a shaker platform. The gel was left washing overnight in excess water. The 
next day the gel was rinsed one last time and switched to a new, clean container 
containing 50 mL of silver nitrate solution (0.833 mLs ammonium hydroxide solution-
1.6% final concentration, 10.66 mLs of 0.36% sodium hydroxide-0.072% final 
concentration, 2 mLs of 19.4% silver nitrate-0.776% final concentration). After 20 
minutes agitation, the gel was washed quickly (approx. 30 seconds each time) 6 times 
with double-distilled water. Citrate developing solution (0.025 g sodium citrate-0.5% 
stock concentration, 0.025 mLs of 37% formaldehyde-0.185% stock concentration, in 
4.85 mLs of ddH20 for 5 mLs total solution), diluted 1:20  (0.025% sodium citrate and 
0.00925% formaldehyde final concentration) in water, was added until brown banding 
pattern appeared. Gel was scanned once desired intensity was reached. The developing 
solution was removed and Kodak Rapid Fixer A solution was used for 5 minutes. The gel 
was washed with water six times for 15 minutes each time and left washing overnight. 
Gel images were taken one last time and gel was stored in water at 4°C for further 
processing. 
 
Western blot 
The 10 mL SDS-polyacrylamide gels were prepared as follows: 5% (for DNA-
PKcs and phospho-DNA-PKcs)- 5.83 mLs dH2O, 2.5 mLs 4X 1.5 M Tris pH 8.8, 1.67 
mLs 30% Acrylamide/Bis, 50 µl 10% ammonium persulfate (APS) (X 0.9), 10 µl 
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tetramethylethylenediamine (TEMED) (X 0.9); 6%-5.5 mLs distilled H2O (dH2O), 2.5 
mLs 4X 1.5 M Tris pH 8.8, 2 mLs 30% Acrylamide/Bis, 50 µl 10% APS (X 0.9), 10 µl 
TEMED (X 0.9); 7.5% 5 mLs dH2O, 2.5 mLs 4X 1.5 M Tris pH 8.8, 2.5 mLs 30% 
Acrylamide/Bis, 50 µl 10% APS (X 0.9), 10 µl TEMED (X 0.9).  The 10 mL stacking 
gel: 4%- 6.2 mLs dH2O, 2.5 mLs 4X 1.5 M Tris pH 6.8, 1.3 mLs 30% Acrylamide/Bis, 
50 µl 10% APS (X 1.1), 10 µl TEMED (X 1.1). Samples were loaded in wells of gel and 
run for approximately 2 hours at 20 milliAmperes (mA)/gel. The protein was transferred 
onto a nitrocellulose membrane for 75 minutes to 2 hours (timing dependent on the 
molecular weight of protein being analyzed) at 100 volts (V) in cold 1X transfer buffer. 
After transfer, the membrane was blocked with either 5% non-fat milk solution in PBST 
(1X PBS, 0.1% Tween-20) or 2% bovine serum albumin (BSA) in TBST (1X TBS, 
0.05% Tween-20) for one hour at room temperature (RT).  Membranes were washed 3 
times, 10 minutes each time, with shaking after blocking. They were incubated in primary 
antibodies overnight at 4°C, with shaking. Proper dilutions were prepared in 1% milk 
PBST or 2% BSA TBST solution.  Antibody solutions were collected, stored at -20°C, 
and re-used multiple times. The next day, membranes were washed 3 times for 10 
minutes each time, with shaking. Membranes were then incubated with HRP-linked 
secondary antibodies, in 1% milk PBST or 2% BSA TBST solution, at a 1:5000 dilution 
at RT for one hour. They were washed 3 times, 10 minutes each time, with shaking. The 
protein signal was detected using enhanced chemiluminescence (ECL) and 
autoradiography. Lastly, the films were scanned and analyzed via ImageJ software. 
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Specifically for DNA-PKcs/phosphoDNA-PKcs blots, only 15 µg of protein was 
included per gel lane. Samples were run on a 5% gel with 100 kDa marker run all the 
way to the bottom and 250 kDa marker at halfway point (in the middle) of gel (with Bio-
Rad protein ladder at 6 µl amount). Gels were run optimally at 200 V for 2 hrs on the 
same day lysate was made and transferred for 2 hours at 200 mA. Five mLs of 10% SDS 
were added to bucket to facilitate transfer. Blocking was sometimes done overnight. For 
DNA-PKcs, 5% milk was used for blocking. Membrane was incubated with primary Ab 
for 2 hours at RT. For phospho-DNA-PKcs blot, blocking was performed for 1 hr at RT 
with 2% BSA in TBST. A 2% BSA in TBST solution was used for primary and 
secondary antibodies, and band of interest should be at the very top of the gel. 
 
Immunoprecipitation 
HEK 293T cells were seeded at 50% confluency in 100 mm plates one day before 
transfection in DMEM media containing 10% FBS and 1% penicillin/streptomycin.  The 
following day cells were transfected with pCMV-Flag-Jade-1 and Flag-5’ UTR- Jade-1 
plasmids (5µg DNA) via Lipofectamine 2000. Cells were treated with DMSO or 10 µM 
MG132 for 12 hours prior to collection. Two days later, the cells were lysed and 
collected in either 750 or 650 µl IP lysis buffer volume. Lysates (1.25 mg protein) were 
pre-cleared with Protein A/G beads for 1 hour at 4°C. Pre-cleared lysates were transferred 
to a new 1.5 microcentrifuge tubes and either Flag or mouse IgG beads were added to the 
lysates. These were left rotating overnight at 4°C.  The following day the beads were 
spun down and washed 3 times with one mL of IP lysis buffer and once with 1x PBS, 
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both solutions containing protease inhibitors. Forty µls of Laemmli sample buffer (2X) 
were added to each tube, boiled for 2-3 minutes, then stored at -20°C.  
Specifically for DNA-PKcs IP, DNA-PKcs can degrade very rapidly/is labile. For DNA-
PKcs IP, lysates were used on same day or stored at -80°C and used within a week. 
Samples were not vortexed or left for overnight IP. Cells were lysed in the early morning 
with all protease inhibitors (no SDS for IP, very soluble protein).  Cell confluence at 50-
70% was best. A 2.5 µl sample was used for protein estimation, and OD was kept to 0.5 
or below. If more than this, Ab did not bind well. If too concentrated, lysate was diluted. 
The 1 mg of lysate was prepared in at least 500 µl IP buffer (can do up to one mL). 
Preclearing was done for 30 minutes with -20/25 µl bed volume (vol), 40/50 µl slurry-
with calibrated Protein A/G PLUS-Agarose (Santa Cruz Biotechnology, sc-2003).  A 2 
hour IP was performed with 20 µl of [0.2 µg/µl] DNA-PKcs mouse mAb, and 1 hour 
Protein A/G bead (40 µl bed vol, 80 µl total vol.) binding incubation in the cold room. 
Washing performed 2-3 times with for first wash for 5 minutes.  The 40 µl of 2X 
Laemmli sample buffer was boiled for 5 minutes at 95°C. At least 5 µl of HiMark Pre-
stained HMW standard (Life Technologies, LC5699), 15 ug for input, was used. 
 
Cytoplasmic/Nuclear Fractionation 
Low salt lysis buffer was prepared as 20 mM HEPES pH 7.4, 10 mM KCl, 2 mM 
MgCl2, with 0.5% NP-40, 100x protease inhibitor cocktail, 10 µg/mL Leupeptin, 10 mM 
NaF*, 1 mM Na3VO4, 1 mM PMSF*, and 1 mM DTT (*added just prior to lysis). High 
salt lysis buffer included 0.5 M NaCl.  Nuclear pellet wash buffer was low salt buffer 
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without NP-40. HK-2 (p) cells were seeded in p150 plates, allowed to reach 
subconfluency, and treated with 500 ng/mL NCS for 2 hours.  Plates were removed from 
incubator, media aspirated and washed with cold 1X PBS. Excess media and PBS were 
removed after letting plate drain at an angle for 2 minutes. Five milliliters of cold 1x PBS 
were added to each plate and cells were scraped into a 15 mL tube. Cells were spun down 
for 5 minutes at 2,000 rpm in 4°C centrifuge. Supernatant was removed from tubes, cell 
pellet was resuspended in 200 µl of cold low salt lysis buffer, and transferred to a 1.5 mL 
microcentrifuge tube. Samples were left in ice for 10 minutes and then spun down at 
2,000 rpm for 3 minutes in 4°C microcentrifuge.  The pellet was saved for nuclear 
fraction isolation. The supernatant cytoplasmic fraction was collected into a new 1.5 mL 
microcentrifuge tube and spun down again at 13,000 rpm for 15 minutes. The 
cytoplasmic supernatant was transferred to a new microcentrifuge tube.  The nuclear 
pellet samples were washed with 500 µl of wash buffer, inverted (with tapping) until 
pellet loosened, and spun down at 4,000 rpm for 5 minutes. Wash buffer was removed by 
pipetting, not aspiration as the nuclear pellet was loose at the bottom. This was repeated 
twice more, for a total of 3 washes. After the last wash is removed, at most 75 µl of high 
salt lysis buffer was added (do not dilute sample too much, nuclear fraction does not give 
much protein).  Samples sat on ice for 10 minutes with low speed vortexing every 2 
minutes, then were spun down at 13,000 rpm for 10 min in 4°C microcentrifuge. Nuclear 
fraction was collected by pipetting up gooey pellet at bottom, bringing it up to the top of 
the tube and then pipetting the supernatant at the bottom into a new microcentrifuge tube.  
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Sensitivity Assays 
Roughly 750 HK-2 cells were seeded in a 96-well plate in total volume of 100 µl. 
The cells were treated the next day in 0-500 nM drug. Drug was diluted in the appropriate 
volume of media and 50 µl was added to each well. After 4 days/96 hours, plates were 
removed and allowed to cool to room temperature. 50 µl of Cell Titer Glo reagent (Cell 
Titer Glo Luminescent Cell Viability Assay, Promega, C7571) was added to each well, 
mixed by pipetting, and left on a shaker for proper lysis. After this, the plate was left 
sitting for 15 minutes to stabilize the reagent. Luminescence was measured with Optima 
plate reader. 
 
Colony Forming Assays 
HK-2 cells were seeded at 500 cells/well the day before treatment. The cells were 
treated with 10, 25, or 50 ng/mL and allowed to form colonies over a two week period. 
The media was removed from the wells and the cells were washed with PBS. Then the 
PBS was aspirated, and a mixed solution of 6.0% glutaraldehyde and 0.5% crystal violet 
was used fix and stain cells for 30 minutes. The solution was removed with water and the 
plates were left to dry at RT. The colonies were counted after overnight drying. 
 
Immunofluorescence 
Cells were seeded on 8 mm circular coverslips, in 12-well plates, the day before 
treatment. The following day they were left untreated or treated with NCS at 500 ng/mL 
or 200 ng/mL, for indicated times. For recovery experiments, media was aspirated from 
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wells then washed once with appropriate media, and fresh media added back for 
appropriate times. Once media was added back, the cells were allowed to recover for 2, 4, 
8, 16, and 24 hours. Plates were removed from incubator and media was removed. Cells 
were washed with cold 1X PBS.  The samples were fixed with 400 µl of 3.7% 
paraformaldehyde (PFA, Electron Microscopy Sciences, 15710) in PBS, pH 7.4 for 15 
min at RT. Fixed samples were washed twice with cold PBS. The samples were 
permeabilized with 400 µl of 0.25% Triton X-100 in PBS for 10 min at RT. Samples 
were washed with cold PBS three times, 5 minutes each.  Samples were blocked with 1% 
BSA in PBST (1X PBS, 0.05% Tween-20) for 30 minutes at RT. Samples were incubated 
overnight with 350 µl of diluted primary antibodies with blocking buffer at 4°C. The 
dilutions for the antibodies were as follows: Jade-1 1:350, γH2AX 1:750, phospho-DNA-
PKcs 1:150. Samples were washed with cold PBS for 4 times, 5 minutes each time, then 
were incubated with 250 µl of 1:1000 diluted fluorophore-linked secondary antibodies 
Rhodamine Red –X goat anti-mouse IgG (H+L) (Life Technologies, R6393) for γH2AX 
or DNA-PKcs and Alexa Fluor 488 goat anti-rabbit IgG (H+L) (Life Technologies, 
A11008) for Jade-1 anti-sera or phospho-DNA-PKcs 1 hour at RT in the dark. Samples 
were washed again with cold PBS for 4 times, 5 minutes each time. The coverslips were 
carefully mounted with 6 µl of Vectashield mounting media (Vector Laboratories, Cat. 
No. H-1200) containing 4’,6 diamidino-2-phenylindole (DAPI) on clean glass slides and 
sealed with clear nail polish. Slides were imaged with a Leica SP5 confocal microscope 
and stored in 4°C in the dark. For γH2AX dynamics experiments, HK-2 parental or stable 
Jade-1 knockdown cells were seeded in 12-well plates (200,000 cells/well). Cells were 
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treated with NCS at a concentration of 50 ng/mL for 1 hour. Media containing drug was 
removed and washed with fresh media. 
 
RT-qPCR 
Cells were treated as above, with NCS or irradiated, and RNA was isolated using 
Zymo Research’s Quick-RNA Miniprep Kit (R1005). RNA was reverse transcribed using 
Verso cDNA Kit (Life Technologies, AB1453B) and Taqman Fast Advanced Master Mix 
(Life Technologies, 4444557) was used in Taqman Gene Expression Assays: ACT B, 
Hs99999903_m1; GAPDH, Hs99999905_m1; Jade-1S and Jade-1L isoform custom 
assays were also created by Life Technologies to detect message levels. 
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CHAPTER THREE: RESULTS 
 Section One: Jade-1 interaction partners, Mass Spectrometry and 
Ingenuity Pathway Analysis 
Given that Jade-1 is known to bind and modify the activity of well-known 
oncoproteins, we sought to identify additional cancer-relevant proteins that Jade-1 
regulates to better understand its function. Thus, we performed Jade-1 co-
immunoprecipitations in kidney cells to discover novel Jade-1 interacting proteins. For 
these initial experiments, two Flag Jade-1 plasmids were transfected, separately, into 
human embryonic kidney, HEK 293T (293T), cells. One of the vectors contained the 
Jade-1 coding sequence alone, while the other included the 5’ untranslated region (UTR) 
of the Jade-1 transcript along with the coding sequence. When translation begins at the 
vector start site the 5’ UTR is included which generates additional amino acids that are 
incorporated into the Jade-1 product, creating a larger protein. However, this is not a 
naturally occurring version of Jade-1. The 5’ UTR-Jade-1 construct allows one to 
visualize Jade-1 at a slightly higher molecular weight than the endogenous protein. Flag 
antibody was used to immunoprecipitate (IP) the overexpressed Flag-tagged proteins in 
the cell lysates, and these samples were run on SDS-PAGE gels for further analysis. Anti-
Flag agarose beads were used as a negative control sample along with the whole cell 
lysates (WCLs) on either side of the IP samples for the immunoblot (Figure 11A). 
Membranes were blotted for Flag-Jade-1 protein using Flag antibody. Another set of 
samples were run on separate gel for silver staining to visualize distinct protein bands in 
the targeted IPs. For these lysates, mouse IgG-agarose beads were used as the negative 
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control. Both overexpressed Flag-tagged Jade-1 proteins were detected in the Western 
blot analysis. We could visualize the efficient expression and IP of both fusion proteins 
due to their size difference without and with the inclusion of the 5’ UTR. As expected, 
the 5’ UTR-containing proteins migrated at a slightly higher molecular weight, around 70 
kDa, compared to construct without this portion, which ran at approximately 65 kDa. We 
also detected these distinct proteins in the IP samples, demonstrating that the Flag pull 
down was successful. Heavy chain IgG bands appeared as prominent bands, at around 50 
kDa, in both the immunoblot and the stained gel due to the samples being run under 
reducing conditions. The overexpressed proteins were highly visible in the silver-stained 
gel, as shown by black arrows (Figure 11B). Furthermore, the gel showed distinct bands 
at different molecular weights compared to the mouse IgG-agarose control IPs. These 
five areas, at approximately 125, 100, 85, 70, and 37 kDa (as pointed out with blue 
arrows, Figure 11B), were excised from the Flag-Jade-1 sample lane and sent to the 
University of Massachusetts (UMass) Medical School Mass Spectrometry Facility for 
protein identification. The samples were run on a nano flow electrospray ionization (ESI) 
liquid chromatography tandem mass spectrometry (LC/MS/MS)-capable Orbitrap 
instrument. The spectral data were analyzed with Mascot protein identification software 
and using Scaffold as the output file. 
  
  
50 
11A 
 
11B 
 
Figure 11. Flag Jade-1 preparatory co-immunoprecipitations in HEK 293T cells for silver stain and mass 
spectrometry. 
A) Flag Jade-1 or Flag 5’ UTR-Jade-1 was overexpressed in HEK 293T cells. Cell lysates were subjected to Flag 
immunoprecipitation and immunoblotted along with respective whole cell lysates (WCL).  Flag-tagged 5’ UTR 
Jade-1 has a higher molecular mass than Flag-Jade-1. B) Silver-stained gel shows immunoprecipitated proteins, 
including dominant Flag-Jade-1 and Flag 5’ UTR Jade-1 bands with Flag IP (black arrows) also seen in a), as 
well as co-immunoprecipitated bands (blue arrows) not seen in the control IPs performed with mouse IgG (right 
lanes).  Abundant protein at 50 kDa represents IgG heavy chain.  Highlighted bands from the Flag-Jade-1 IP 
(blue arrows) were excised from the gel and subjected to mass spectrometry. IP, immunoprecipitation; IB, 
immunoblot; UTR, untranslated region; mIgG, mouse immunoglobulin G. 
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The complete list of proteins was submitted for unbiased interpretation using 
Ingenuity Pathway Analysis (IPA). IPA is a bioinformatics platform that uses a manually 
curated database to identify significant pathways based on data provided by the 
researcher. The software categorized the proteins into the major biological processes 
listed in Table 2, which were: DNA double-strand break repair by non-homologous end 
joining, cell cycle control of chromosomal replication, telomere extension by telomerase, 
Granzyme B signaling, and mismatch repair in eukaryotes. The IPA program also creates 
visual networks of these pathways based on the literature as shown in Figure 12. In the 
graphic, the main proteins involved in NHEJ initiation are highlighted. These proteins, 
DNA-PKcs, Ku70 and Ku80, were found to associate with Jade-1. The solid lines 
between proteins signify that there is direct interaction between them, while the dotted 
lines represent an indirect connection. Table 3 lists the known Jade-1 interactors found in 
the mass spectrometry analysis, as well as the number of unique peptides specifically 
related to each molecule.  These known interactors include the histone acetyltransferase 
HBO1/MYST2, the minichromosome maintenance factors MCM 3, 5, and 7, as well as 
multiple histone proteins. Several additional DNA repair pathways and proteins were also 
identified in the analysis. Mismatch repair proteins included MSH2 and DNA polymerase 
delta 1 (POLD1), while DSB proteins, involved in either NHEJ or HRR that potentially 
associate with Jade-1 include DNA-PKcs, Ku70, Ku80 and PARP1. Some of the proteins 
are involved in multiple repair pathways, such as PARP1, which also influences NER and 
BER. The highest number of peptides identified from the pull down were from histone 
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H4, MCM7, POLD1, and DDB1, with at least 7 unique peptides detected. The other 
proteins had an average of 3 unique peptides. 
Following these analyses, we decided to focus our studies on DNA repair, 
particularly DSB repair, as DSBs are the most detrimental lesions that can occur in cells 
and may lead to cancer. Moreover, chromosomal instability is a prominent characteristic 
of ccRCC and is due to defects in DSB repair, making this pathway clinically relevant. 
We developed the following objectives to elucidate the connection between Jade-1 and 
DNA repair in kidney cancer. 
Aim 1: We sought to verify the interactions between Jade-1 and DNA-PKcs and 
DDB1 by co-immunoprecipitations. Another related goal was to visualize Jade-1, DNA 
repair proteins and DSB marker γH2AX through immunofluorescence studies. Co-
localization with γH2AX by immunofluorescence would indicate that Jade-1 was acting 
directly on repair proteins at sites of damage. 
Aim 2: We also wished to determine if Jade-1 protein and mRNA levels changed 
in the presence of DNA damage in kidney cells. For these experiments we used kidney 
model cell lines, 293T, 786-O, and HK-2 cells to determine a relevant kidney response 
and treated them with agents known to induce DSBs. We also assessed the influence of 
pVHL in ccRCC 786-O cell lines by stably introducing either an HA-VHL construct or 
an empty vector as control. 
Aim 3: As functional assessments of role of Jade-1 in DSB repair we used HK-2 
cells with or without stable JADE knockdown to gauge the ability to contend with DSB 
damage, in the short and long-term, through sensitivity assays and colony forming assays. 
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In addition, we used these lines to quantify the resolution of DSBs through γH2AX 
dynamics at damage sites. 
Through these experiments we expected to elucidate a novel tumor suppressor 
role for Jade-1. The knowledge gained from this work should provide a better 
understanding of ccRCC pathogenesis and help develop improved treatments affecting 
DNA repair for this malignant disease. 
Table 2. Categorization of major biological processes identified by Ingenuity Pathway Analysis. 
 
Table 3. Key Jade-1 co-immunoprecipitated proteins identified by mass spectrometry analysis. 
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12 
  
Figure 12. Visual representation of DNA double-strand break repair by non-homologous end joining network 
using Ingenuity Pathway Analysis. 
Circled and labeled proteins are those found to associate with Jade-1 and form the DNA-PK holoenzyme, which 
initiates NHEJ repair. Jade-1 is also highlighted here, connected with KAT7 (HBO1/MYST2), a known Jade-1 
interactor. Solid lines represent established interactions between proteins while dotted lines indicate an indirect 
connection with the proteins. 
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Section Two: Verification of interactions through Jade-1 and DNA-PKcs co-
IP 
We focused our studies on the proteins involved in DNA repair mechanisms as 
DNA damage and subsequent response to this stress could impact cells and promote 
oncogenesis, including ccRCC. DNA-PKcs is involved in NHEJ, one of the most 
important DSB repair mechanisms, as chromosomal aberrations can have major 
deleterious effects on cell function. DNA-PKcs is highly expressed in all cells, as its 
persistent presence is important when cells must act quickly to deal with DNA damage. 
Moreover, the NHEJ repair mechanism is enlisted in all steps of the cell cycle, compared 
to HR, which is mainly active during S and G2 phases of the cell cycle. 
Flag Jade-1S was again overexpressed in HEK 293T cells and 
immunoprecipitated with Flag antibody to detect endogenous DNA-PKcs. There was a 
visible interaction of the DNA-PK component when the overexpressed protein was pulled 
down. The catalytic subunit breakdown product was found to be between 150 and 250 
kDa, approximately around 170/180 kDa, in both the whole cell lysates and the IPs 
(Figure 13A, DNA-PKcs IB, all lanes). In contrast, a positive interaction was not detected 
in Jade-1 IBs following DNA-PKcs immunoprecipitation. This may be due to the region 
where the DNA-PKcs antibody is binding to DNA-PKcs. The epitope that the antibody 
targets is expansive and it is possible that this interferes with the area where Jade-1 binds. 
Another factor to take into account is the abundance of the proteins. DNA-PKcs is a 
highly abundant protein, while, Jade-1 is usually rapidly degraded. The interaction 
between Jade-1and DNA-PKcs may be very transient. 
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In addition, the lack of visible interaction in our immunoblots could be due to the 
fractions that are being isolated. DNA-PKcs binds very strongly to DNA and we may not 
be collecting this fraction in our IPs. The DNA-PKcs association with the Jade-1 pull 
may be the portion that is disassociated from DNA. However, because overall Jade-1 
levels are lower and their interaction may be rapid we cannot detect Jade-1 in the reverse 
IP. This may have also been the reason why the interaction between DNA-PKcs and 
Ku70 was also weaker than expected in our IP experiments (Figure 13C, lanes 2 and 9, 
high exposure Ku70 IB). 
Another set of cells was also treated the MG132 protease inhibitor to enrich the 
association between proteins that are potentially targeted by the proteasome for turnover. 
There seemed to be a slight enhancement of immunoprecipitated DNA-PKcs in the 
MG132-treated cells compared to the untreated condition (Figure 13A, DNA-PKcs IB, 
last 2 lanes). Again, no Flag Jade-1 protein was detected in the presence of MG132 in the 
DNA-PKcs IB. 
Next, we sought to determine if there was binding between the two endogenous 
proteins in the 293T cells. For this co-IPs in this experiment, we used the Jade-1 antisera 
to pull down endogenous Jade-1 and DNA-PKcs. As a positive control for binding 
between Jade-1 and a known interactor, we immunoprecipitated β-catenin and again used 
MG132 to enhance the protein-protein interaction. Previous studies done in our 
laboratory demonstrated that both Jade-1 and β-catenin are targeted by the proteasome for 
degradation. Moreover, Jade-1 is an E3 ubiquitin ligase for β-catenin, so inhibiting the 
proteasome sustains their interaction. We identified the interaction between the 
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endogenous Jade-1 and endogenous DNA-PKcs in the DNA-PKcs IB (Figure 13B, lanes 
2 and 5). Interestingly, as an important negative control, in the β-catenin 
immunoprecipitation there was no detectable association with DNA-PKcs in either 
condition (Figure 13B, DNA-PKcs IB, lanes 3 and 6). However, we visualized the known 
interaction between endogenous Jade-1 and endogenous β-catenin proteins in the lysates. 
As expected, there was also an increase in the abundance of each protein and 
enhancement of the interaction with MG132 treatment (Figure 13B, β-catenin and Jade-1 
IBs, lanes 4, 5, and 6). 
The NHEJ repair mechanism is highly active in response to DSB damage. We 
sought to determine if the interaction between Jade-1 and DNA-PKcs might increase in 
the presence of the radiomimetic agent that induces DSBs, neocarzinostatin, (NCS) 
(Goldberg, 1991; Smith, Bauer, & Povirk, 1994). We treated the 293T cells with NCS 
and performed co-IPs of Jade-1, DNA-PKcs, and Ku70, which is a known binding 
partner of the catalytic subunit and another component of the DNA-PK holoenzyme. 
MG132 was again used to test for the impact of proteasome inhibition on the DNA repair 
proteins in these cells. In the presence of NCS there seemed to be a modest increase in 
DNA-PKcs levels (Figure 13C, DNA-PKcs IB, lane 6 versus lane 5). Proteasome 
inhibition only seemed to increase DNA-PKcs protein slightly and diminish Ku70 levels 
(Figure 13C, lane 8). Without DNA damage treatment there was a detectable interaction 
between Ku70 and lower molecular weight products of DNA-PKcs, as is seen with Jade-
1 (Figure 13C, DNA-PKcs IB, lane 1-low exposure and lane 4-high exposure, 
respectively). Immunoprecipitation of DNA-PKcs, without NCS, showed that there was 
  
58 
some binding to Ku70 and this was again visible with NCS treatment (Figure 13C, Ku70 
IB, lanes 2 and 9-high exposure). There was no detectable interaction between Jade-1 and 
Ku70 in either condition. However, in the presence of the DSB damaging reagent, we 
were able to detect both Ku70 and Jade-1 association with the full-length form of the 
catalytic subunit (Figure 13C, DNA-PKcs IB, lane 7-high exposure and lane 10- low 
exposure). Importantly, these experiments confirm an interaction between endogenous 
Jade-1 and endogenous DNA-PKcs. 
13A 
 
13B 
 
 
 
  
59 
 
13C 
 
Figure 13. Endogenous Jade-1 binds endogenous DNA-PKcs. 
A) Flag IP co-immunoprecipitates endogenous DNA-PKcs. HEK 293T cells were transfected with Flag Jade-1 
and treated with either DMSO or MG132. Flag Jade-1 or endogenous DNA-PKcs were immunoprecipitated 
with Flag or DNA-PKcs antibodies. B) Endogenous Jade-1 IP, but not β-catenin IP, co-immunoprecipitates 
endogenous 170 kDa DNA-PKcs.  Cells were treated with either DMSO or MG132. C) Induction of DSBs 
promotes co-immunoprecipitation of endogenous, full-length DNA-PKcs with endogenous Jade-1.  HEK 293T 
cells were treated with NCS (500 ng/mL) or left untreated for 14 hours. Lysates were subjected to co-IPs with 
Jade-1, Ku70, DNA-PKcs antibodies. Abbreviations, Flag, F; DNA-PKcs,D; β-catenin, β-cat; neocarzinostatin, 
NCS; MG132, MG. 
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Section Three: Jade-1 abundance in presence of DNA damage- protein and 
mRNA analysis 
We wanted to evaluate Jade-1 protein levels in the presence of DSB damage in 
kidney cells. A study published by Wan et al. found that both Jade-1 protein and mRNA 
levels increased in the presence of NCS in breast cancer cells (Wan et al., 2013). We 
performed the same experiment in the 293T cell line and the 786-O renal cancer cell line. 
The 786-O cells are VHL-deficient and express very low levels of Jade-1. The 293T and 
786-O cells were treated with either 500 ng/mL or 200 ng/mL NCS, respectively. In the 
293T cells Jade-1 levels increased close to three-fold above baseline levels at four hours. 
Jade-1 induction increased even further at the eight hour time point, but dropped at 16 
hours. Jade-1 increased again at the 20 hour time point and was elevated until 24 hours.  
Jade-1 abundance peaked at 24 hours with an 8.5 fold change above control levels 
(Figure 14A). Jade-1 levels also increased in 786-O cells. In this experiment, a two-hour 
time point was included, and there was a two-fold increase in Jade-1 protein compared to 
the untreated cells. At the four-hour treatment time, Jade-1 induction was 2.7 fold over 
baseline. Jade-1 protein was highest at the 16-hour time point, reaching 3.4 fold 
induction. There seemed to be a decrease at 24 hours, but densitometry analysis revealed 
that Jade-l levels were sustained at 3.3 fold over the untreated cells when normalized to 
the β-actin loading control (Figure 14C).  
JADE1 message levels were also analyzed via real-time quantitative PCR 
analysis. For these experiments the cell lines were either left untreated or evaluated at the 
4, 8, and 24 hour treatment time points. In the 293T cells, JADE1 expression levels 
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gradually decreased over time. At 24 hours there was a 50% reduction in mRNA, and this 
was statistically significant compared to the untreated cells. At the four and eight hour 
time point there was a 20% and 25% drop in expression, respectively. However, this was 
not statistically significant compared to the untreated cells. For the renal cancer cells, 
there was very little change between the untreated control and four hours of NCS 
treatment. When the cells were treated for eight hours with NCS there was a 100% 
increase in JADE1 levels. This was not statistically significant though, due to variations 
between experiments. However, this increase dropped back down to close to baseline by 
24 hours. Statistics were done for three independent mRNA experiments with ANOVA 
followed by t-test. When taking into account Bonferroni correction, a p-value less than 
0.0125, was considered statistically significant. In general, for the 786-O cell line, the 
JADE1 levels seemed steady over time (Figure 14D).  
Overall, these results suggest that while Jade-1 protein is induced in response to DNA 
damage, the upregulation does not seem to be at the message level, as Jade-1 mRNA was 
not induced in this setting. 
14A 
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Figure 14. Jade-1 protein, but not message levels, increase in response to DNA DSB damage in 293T and 786-O 
cells. 
A) 293T cells were treated with NCS (500 ng/mL) over several time points. B) 293T cells were left untreated 
(untd) or treated with NCS (500 ng/mL) for 4, 8, and 24 hours. C) 786-O cells were subjected to DNA damage 
with NCS (200 ng/mL) and lysed at the indicated time points. D) 786-O cells were subjected to DNA damage 
with NCS (200 ng/mL) and lysed at the indicated time points. Jade-1 antiserum was used to detect Jade-1. Jade-
1 levels were normalized to β-actin by densitometry using ImageJ software. RNA was isolated and JADE1 and 
GAPDH levels were assessed with Taqman assay and tested for significance using single-factor ANOVA with 
Bonferroni t-test correction. The test assumed samples had equal variances and a value of <0.05 was considered 
significant. 
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Section Four: Jade-1 protein levels in renal cancer cells stably expressing 
either HA-empty vector or HA-VHL construct 
  As pVHL is known to stabilize Jade-1 we wondered whether pVHL might 
influence Jade-1 induction when present in the 786-O cells. Thus, along with the studies 
done in the aforementioned cell lines, 786-O cells stably expressing either a 
hemagglutinin (HA) empty vector (V0) or HA-VHL were also tested using NCS. These 
pooled cells efficiently express wild-type (wt) pVHL and there is also visible detection of 
Jade-1 compared to the empty vector cells (Figure 15A). These two cell lines were 
treated with 200 ng/mL NCS for different time points. However, we saw no major 
increase in Jade-1 protein abundance, in either cell line, when they were subjected to 
DSB damage. At the two-hour time point there was a 10% increase in Jade-1 levels for 
both lines and this increased another 10% at the four-hour time point for the HA-VHL 
line. In contrast, Jade-1 levels fell below baseline at the four hour time point in the HA-
V0 cells. Then, at the eight-hour time point, there was a return to baseline levels for both 
lines and another fluctuation at 16 hours. At the longest time point, 24 hours, both lines 
had similar levels of Jade-1, at about 10-20% below baseline (Figure 15B).  
In brief, we were not able to determine if the increase in Jade-1 abundance in the stable 
786-O cell lines was definitively associated with the presence of pVHL. We suspect the 
Jade-1 increase is unrelated to pVHL, as the parental 786-O cells showed appropriate 
Jade-1 induction. It would be worthwhile to test other VHL-expressing renal cancer cells 
undergoing DSB damage. 
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Figure 15. Jade-1 levels are unchanged in 786-O stable cell lines. 
A) Renal cancer cell lines stably expressing either an HA empty vector (HA-V0) or pooled cells expressing an 
HA-VHL construct were evaluated for Jade-1 protein levels in response to DSBs. B) Stable 786-O cells were 
seeded and treated with NCS (250 ng/mL) for various time points or left untreated for the longest time period 
indicated. Cell lysates were collected and subjected to SDS-PAGE. 60 µg of protein sample were loaded in well 
to visualize Jade-1 and β-actin levels. ImageJ was used for densitometry analysis. 
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Section Five: Jade-1 protein levels increase in adult proximal tubule cells 
We also examined if Jade-1 induction occurred in response to DNA damage in the 
adult, immortalized proximal tubule HK-2 cells. The HK-2 cells were treated for 2, 4, 8, 
and 24 hours with NCS. There was a 1.36-fold induction in Jade-1 levels at the earliest 
treatment time point compared to untreated cells. However, this dropped below baseline 
at the four hour treatment time. Protein levels then rose again to 1.18 fold above baseline, 
at the eight hour time point. At the longest treatment time, Jade-1 levels remained at 
around this level, slightly above untreated levels (Figure 16A).  
As a follow up to the approximately 40% increase in Jade-1 levels at the two hour time 
point, we investigated whether Jade-1 induction occurred earlier in these cells. We tested 
two earlier time points with NCS treatment, 30 and 90 min, along with similar time 
points from previous experiments. We found that Jade-1 levels increase at 30 minutes in 
the presence of DSB damage. This rose to 1.5 fold over untreated levels at 90 min and 
then dropped at the next time point, 3.5 hours (Figure 16B). These results demonstrate 
that Jade-1 levels rose early on in the model renal cancer precursor cells. We also 
visualized this upregulation in Jade-1 in our immunofluorescence studies using HK-2 
cells (Figure 16C). 
  
67 
16A
 
16B
 
  
68 
16C
 
Figure 16. Jade-1 protein levels increase early on in adult proximal tubule cells following induction of DSBs. 
A) HK-2 cells were treated with NCS (500 ng/mL) for 2, 4, 8, and 24 hours. Cell lysates were collected and Jade-
1 and α-tubulin levels were detected using Jade-1 antiserum and purified α-tubulin antibody, respectively. B) 
HK-2 cells were treated at earlier time points, as indicated, and lysates for Jade-1 and β-actin detection. ImageJ 
software was used for densitometry analysis. C) Representative immunofluorescence image indicating increase 
in Jade-1 protein after treatment with NCS (250 ng/ml, 1 hr). 
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Section Six: Jade-1 increases in cytoplasmic fraction in kidney cells in 
presence of NCS 
 The consistent Jade-1 induction in the kidney cells in response to DSB damage 
led us to investigate the subcellular region where this increase might happen. For these 
experiments, 293T cells were treated once again with NCS for 13 hours and subsequently 
lysed for cytoplasmic/nuclear fractionation. These studies revealed that there was in 
increase in the cytoplasmic levels of Jade-1. There was a 60% increase in Jade-1 levels in 
this fraction when compared to the untreated levels. Surprisingly, Jade-1 levels seemed to 
drop in the nuclear region of the cells. The amount of Jade-1 present in the nucleus 
dropped 40% compared to the untreated nuclear cell extract (Figure 17A). We also tested 
this in the HK-2 cell line. This time cells were treated for two hours, less time than the 
293T cells. Again we saw a substantial increase in Jade-1 abundance in the cytoplasmic 
fraction over untreated cells. There was approximately a 120% change in Jade-1 levels 
when treated with the DNA damage-inducing agent. Interestingly however, we saw a 
70% decrease in Jade-1 levels at this time point in the nuclear fraction (Figure 17B). 
Overall, this suggested that the increase observed in the WCLs of Jade-1 were mainly due 
to the increase in the cytoplasmic fraction. 
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Figure 17. Jade-1 increases in the cytoplasmic fraction in kidney cells. 
A) 293T cells were treated with NCS for two hours and subcellular fractionation was performed to isolate the 
cytoplasmic and nuclear proteins. B) HK-2 cells were treated with NCS for two hours and cytoplasmic and 
nuclear extracts were isolated. Samples were ran via SDS-PAGE and immunoblotted for Jade-1, α-tubulin, and 
fibrillarin. Graphical representation of these experiments was created using Excel and α-tubulin normalization 
for cytoplasmic fraction and fibrillarin for nuclear fraction; IB, immunoblot; n=1 for each cell line. 
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Section Seven: Jade-1 signal in the presence of DNA damaging treatments 
 During this time we also tested the parental and along with stable HK-2 cell lines 
generated previously in our laboratory. Briefly, the HK-2 cells were used to create three 
stable cell lines, a non-targeting control shRNA plasmid (nonsi), a plasmid that depleted 
the both the long and short Jade-1 isoforms (si25), and another one which reduced only 
the short isoform (si47). The original HK-2 cell line used was treated with either DMSO 
or doxorubicin, which is an antibiotic and antineoplastic agent that also induces DSBs 
(Siu et al., 2004). Jade-1 levels increased 1.4 fold over the control treated cell line at the 
two-hour time point. Protein rose even further at four hour treatment time and then 
dropped at the eight and 16 hour time points with doxorubicin. At the longest time point 
tested, 24 hours, Jade-1 levels were close to 1.8 fold over the vehicle-treated cells (Figure 
18A). The nonsi cell line was treated with cisplatin, a known antitumor drug that induces 
intrastrand crosslinks (ICLs) (Siddik, 2003). We found that Jade-1 protein levels rose as 
early as one hour with 50 µM treatment. At the four- and eight-hour time point treatment 
Jade-1 increased slightly and reached close to a two-fold change over DMSO-treated 
cells at 24 hours (Figure 18B). These data reveal once again that Jade-1 protein levels are 
altered due to exposure to DNA damaging agents. Even though there are fluctuations at 
different time points, there is early induction of Jade-1 protein levels. This response 
suggests that Jade-1 acts directly and promptly when a cell is under genetic stress. 
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Figure 18. Jade-1 increases in presence of other DNA damage agents. 
A) HK-2 parental cells were treated with either DMSO (veh) or doxorubicin (400 ng/mL), a known 
antineoplastic drug that induces DSBs, for various time points. B) HK-2 nonsilencing cells were treated with 
DMSO or cisplatin (50 µM), another chemotherapeutic agent that produces intrastrand crosslinks. WCLs were 
collected and Jade-1 and β-actin were detected using antisera and β-actin antibody. ImageJ software was used 
for densitometry analysis. Jade-1 levels were normalized against β-actin and fold change was compared against 
vehicle treatment for 24 hours; hrs, hours; IB, immunoblot. 
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Section Eight: Differential sensitivity of JADE1 knockdown cells compared to 
parental and nonsilencing cells 
Next, due to the increase in Jade-1 protein levels in the kidney cells when 
subjected to DNA damage, we decided to evaluate cell viability of the HK-2 stable cell 
lines in the presence of NCS through sensitivity assays. Cells were treated with the DSB 
damaging agent for four hours with the following doses: 0, 5, 50, 250, and 500 nM. At 
the lowest dose, 5 nM, there was 10% viability difference between the parental, nonsi, 
and si25 knockdown cell lines. The parental line viability was 25% while the nonsi and 
si25 was 34%. At this dose, there was a 20-30%% difference in si47 survival, 55%, 
compared to the other lines. The viability of all lines remained stable at the 50 nM NCS 
concentration. Surprisingly we found that the si25 cell line had similar viability 
characteristics as the parental and nonsi cell lines. The lines’ survival at the lowest dose 
given did not change much at, 50 nM. The parental, nonsi, and si25 lines had markedly 
diminished survival at the 250 nM NCS dose, with only 7-8% viability. This dropped to 
2-4% at the highest concentration. As for the si47 line, the viability dropped to 20% and 
10% at 250 nM and 500 nM, respectively. We found that the cells with stable knockdown 
of the JADE1 short isoform were less sensitive than the other cell lines to NCS. All of the 
lines had 10% or lower survival at the highest concentration of NCS, 500 nM (Figure 19). 
These observations suggest that cell survival in response to DNA damage is dependent on 
levels of Jade-1 proteins. Previous studies have indicated that loss of a particular DNA 
repair protein can make cells less sensitive to DNA damage. Such is the case with the 
mismatch repair gene, Msh2. Homozygous deletion of Msh2 in mouse embryonic cells, 
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produced a mutator phenotype, assessed by changes in length of microsatellite markers. 
Mutant cells had increased lengths in microsatellite markers: D17Mit7 and D14Mit15. 
Additionally the Msh2-/- cells were less sensitive to MNNG, a methylating agent that 
methylates guanine residues at the O6 position. As a result, thymidine is incorporated into 
the opposite strand during replication instead of cytosine. The Msh2-null cells had 
increased viability compared to either heterozygous or wild-type cells. Moreover, mice 
were generated with these cells lines and, although they were healthy at birth, Msh2-/- 
mice were predisposed to cancer while the wild-type mice were cancer-free throughout 
the study (de Wind, Dekker, Berns, Radman, & te Riele, 1995). We speculate that such is 
the case here, that Jade-1 plays a key role in DNA damage sensing and repair, and that 
loss of Jade-1 renders cells less sensitive to damage. Jade-1 loss may allow the cells to 
repair more rapidly through the NHEJ pathway. However, over time cells would 
accumulate more mutations, which would promote tumorigenesis. In addition, the levels 
of the different Jade-1 isoforms may be key, as si25 silences both JADE1S and JADE1L 
while si47 silences only JADE1S. 
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Figure 19. JADE1S knockdown cells tend to be less sensitive to DSB damage treatment compared than parental, 
control and double JADE1S and JADE1L knockdown HK-2 lines.  
HK-2 cells were treated with NCS for four hours and then fresh media was added in 96-well plates. Four days 
later, the cell viability assay was performed using Cell-Titer Glo reagent and reading luminescence using a plate 
reader. 
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Section Nine: Differential colony forming capabilities between parental, 
nonsilencing and JADE1 knockdown cells 
As another way to evaluate the contribution of Jade-1 to DSB repair process we 
tested the clonogenic capabilities of the HK-2 lines. Colony forming assays are an 
informative method to determine if a protein is involved in the DNA damage response 
system. This allows one to visualize and quantify how cells respond to and recover from 
DNA damage. The HK-2 cells were plated and treated with NCS for four hours. After 
this treatment time cells were re-seeded into 6-well plates and incubated for a period of 
two weeks.  This allowed for the cells to repair any damage acquired and subsequently 
continue to proliferate once the stress was dealt with properly. In the first experiment the 
parental and nonsi cells, which have normal Jade-1 levels, had fewer colony numbers 
than the si25 and si47 cells with reduced Jade-1 levels. For this experiment, we treated 
the cells with 500 ng/mL NCS and then re-seeded 59,000 cells total for each group. The 
quantitation of colonies that grew was 26 colonies (0.044%) for the baseline Jade-1 levels 
and 90 (0.15%) for the cells with stable JADE1 knockdown after NCS treatment. Thus, 
there was a 3.5-fold increase in the number of colonies in the knockdown cells over the 
cells with normal Jade-1 levels. We repeated this experiment and found this to be 
consistent between the two groups of cell lines. This time, however, we treated the cells 
with a lower concentration of NCS (25 ng/mL) to potentially increase the number of 
colonies formed and we also re-seeded the cells at lower numbers per well (350 for each 
line). In the second assay there were again more colonies in the JADE1 knockdown lines 
compared to the cell lines with baseline Jade-1 levels (Figure 20). Interestingly, there 
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were lower numbers of colonies, 16 (2.3%) and 74 (11%), respectively. This time the fold 
change between the two groups of cells was even higher, with 4.6-fold more colonies 
from the knockdown lines compared to the Jade-1 normal cell lines (Table 4). We 
calculated the surviving fractions for each group of cell lines in this experiment. These 
were 16.3% and 42.3% for JADE1 baseline and JADE1 knockdown cells, respectively. 
This was a 2.6 fold increase in the JADE1 knockdown cells’ ability to survive and 
proliferate after exposure to DSB damage. 
 These experiments support the idea that Jade-1 plays an important role in DNA 
repair in response to DSBs.  As noted above, deletion of a key repair protein may make 
cells less sensitive to DNA damage and promote recovery, although potentially at the 
expense of fidelity of the DNA repair. 
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Figure 20. Stable JADE1 knockdown cells form more colonies than cells with baseline JADE1 levels after 
induction of DSB damage. 
HK-2 cells cell were treated with NCS for four hours and reseeded in 6-well plates. Cells were allowed to grow 
for two weeks and colonies were stained and counted. 
Table 4. HK-2 cell colony numbers after treatment with NCS. 
 
  
  
80 
Section Ten: γH2AX dynamics differ in adult proximal tubule cells with 
normal JADE1 levels versus those with JADE1 knockdown  
 We decided to evaluate any differences with regards to DSB damage in kidney 
cells. We focused our immunofluorescence studies in the adult proximal tubule cells as 
these are the most physiologically relevant cells. These cells are thought to be the 
precursor cells to RCC and the stable JADE1 knockdown cells make them a suitable 
model system to evaluate how Jade-1 may influence DNA repair processes. First, 
confirmation of Jade-1 protein levels differed among the parental and the knockdown cell 
line. We collected whole cell lysates and blotted again Jade-1 and β-actin. We were able 
to verify that Jade-1 was adequately diminished in the si47 cells (Figure 21A).  
One of our objectives was to visualize the resolution of DSB damage marker, γH2AX, 
after exposing the cells to NCS and allowing them to recover for various time points up 
to 24 hours. Through preliminary experiments we found that at 50 ng/mL NCS treatment 
we could detect differences between untreated, treated, and recovered cells. We either left 
the HK-2 parental and si47 cells untreated or treated with 50 ng/mL NCS for one hour 
and then allowed them to recover for 0, 2, 4, 16, and 24 hours. In the untreated cells we 
saw there that there were higher percentage of parental cells that were positive for 
γH2AX signal. Around 20% of the cells had at least ten foci indicating DSB damage was 
present (at least 100 cells were included for this assessment). When the cells were 
subjected to DSB damage and immediately processed for IF there was an increase to 80% 
positively-damaged parental cells and this dropped to around 50% positive cells at the 
four and 16 hour time points. At 24 hours the amount of DSB damage present, as 
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represented by the γH2AX signal, returned to baseline. On the other hand, the 
knockdown lines displayed a lower level γH2AX, with around 10% positive damaged 
cells, at baseline. This increased to approximately 40% DSB-damage positivity directly 
after treatment with NCS. This dropped to around 30% at 2 and 4 hours recovery time 
points. Once again baseline percentage of γH2AX positive cells was reached at 24 hours 
(Figure 21B). These results indicate that there may be dysfunctional DNA damage 
signaling taking place in cells with reduced Jade-1 levels. The knockdown cells are less 
sensitive to DSB damage, in general, and perhaps they are more readily able to deal with 
genetic stress and so this γH2AX is diminished even in normally-growing cells. 
21A 
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Figure 21. γH2AX dynamics are altered in stable JADE1 knockdown cells. 
A) Whole cell lysates were collected and analyzed via SDS-PAGE to verify efficient knockdown of Jade-1. β-
actin antibody was used to ensure equal sample loading. B) HK-2 parental and si47 were seeded on 8 mm 
coverslips in 12-well plates and either left untreated or treated with NCS (50 ng/mL) for 1 hour. Drug was 
removed and cells were allowed to recover from treatment for 0, 2, 4, 16, and 24 hours. Coverslips were then 
processed for immunofluorescence as described in Materials and Methods section. γH2AX was used to highlight 
DSB damage signal and image analysis was done using ImageJ software to quantify foci. The presence of at least 
ten nuclear foci was required to assign a cell as DNA damaged. At least 100 cells were counted for each 
condition. 
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Section Eleven: Jade-1 localizes to DSB damage foci indicated by γH2AX 
 To further to support the idea that Jade-1 is actively involved in DNA repair we 
assessed the localization of Jade-1 in cells subjected to DSB damage through IF 
experiments. We stained HK-2 parental cells with Jade-1 and γH2AX signal after treating 
the cells with 250 ng/mL NCS for one hour. We compared these cells to untreated cells 
and found that there were undetectable γH2AX-positive cells in unperturbed cells. Jade-1 
signal was found in both cytoplasmic and nuclear compartment of the cells (Figure 22A, 
first panel). When the cells were under exogenous exposure to the DNA damaging agent 
there were several distinct foci that appeared in the cells. Additionally, although not 
quantified, there was brighter signal deriving from the Jade-1 staining in NCS-treated 
cells. The staining appeared very strongly in the nucleus, but also increased in the 
cytoplasm (Figure 22A, second panel). This coincides with our fractionation studies 
where we saw Jade-1 levels increase in the cytoplasm in response to DSB damage. Jade-1 
may act within both nuclear and cytoplasmic compartments when the cells are 
undergoing genetic stress. The cells were also treated with other known DSB-inducing 
agents: doxorubicin and camptothecin (CPT), which is a topoisomerase I inhibitor with 
anticancer activity. These were given at a concentration of 1 µM for one hour and DMSO 
was used as a control treatment for these drugs. Once again there were low levels of 
γH2AX-positive foci in the cells in DMSO-treated cells and Jade-1 found diffusely 
throughout the cell (Figure 22A, third panel). In the cells treated with either doxorubicin 
or CPT there were a number of DSB damage foci present in the cells. The Jade-1 signal 
in the nucleus again seemed brighter with both of these individual treatments (Figure 
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22A, fourth and fifth panels). All the conditions with DSB-damage treatment revealed 
that some Jade-1 did co-localize with γH2AX marker. 
Section Twelve: Phospho-DNA-PKcs co-localizes with γH2AX at sites of DSB 
damage 
 We wished to verify that DSB repair, via NHEJ, was taking place in our model 
cell line. DNA-PKcs autophosphorylation at certain amino acids indicate whether active 
NHEJ status. Modification at serine 2056 is known to represent active repair. Apart from 
the Jade-1 and γH2AX staining to visualize co-localization, we set up another experiment 
to visualize γH2AX co-localization with phospho-DNA-PKcs. The HK-2 cells were 
again treated with NCS, doxorubicin, or CPT. Untreated cells or DMSO-treatment was 
used as the control condition. In the untreated cells there seemed to be a weak phospho-
DNA-PKcs signal and no visible DSB damage occurring in the cells (Figure 22B, top 
panel). However, both signals dramatically increased in cells treated with NCS. There 
were very bright foci with phospho-DNA-PKcs staining as well as γH2AX. There was 
also overlap between both signals in spots throughout the nucleus (Figure 22B, second 
panel). This was also seen when the cells were treated with the topoisomerase inhibitors. 
In DMSO-treated cells there were very low to undetectable levels of either phospho-
DNA-PKcs or γH2AX signal (Figure 22B, third panel). In the doxorubicin-treated cells, 
the phospho-DNA-PKcs brightness did not seem to increase as much as it had for NCS, 
but there was still co-localization visible in the nucleus of these cells (Figure 22B, fourth 
panel). As with the NCS and doxorubicin-treated cells, the γH2AX signal appeared in 
distinct foci with CPT treatment. Also, the phospho-DNA-PKcs signal brightness seemed 
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to increase much more in the nucleus with this treatment compared to doxorubicin. There 
was also much more detectable co-localization between the DSB-damage marker and the 
active NHEJ repair phospho-DNA-PKcs signal (Figure 22B, fifth panel). These results 
indicate that, in the presence of DSB damage agents, the HK-2 cells DNA respond to this 
stress as seen by the γH2AX induction. At some of these foci, active NHEJ repair is 
taking place as demonstrated by the increase in DNA-PKcs phosphorylated at serine 
2056. Moreover, when these kidney cells are stained with Jade-1 and γH2AX there is also 
detection of co-localization. Taken together this suggests that some Jade-1 molecules are 
found at DSB sites and that they could also be undergoing NHEJ repair. 
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Figure 22. Jade-1 co-localizes with γH2AX at DSB damage foci while phospho-DNA-PKcs representing sites of 
active NHEJ repair also localized with γH2AX. 
A) HK-2 cells, growing on coverslips, were treated with NCS, doxorubicin (Dox), or camptothecin (CPT). 
Untreated or DMSO-treated cells were used as control conditions. Antibody targeting DSB damage marker, 
γH2AX, and Jade-1 antisera were used as primary antibodies. Secondary antibodies conjugated with fluorescent 
probes, Rhodamine Red and Alexa Fluor 488, were used to detect γH2AX and Jade-1, respectively. Coverslips 
were mounted on glass slides with Vectashield containing DAPI to detect nucleus. A Leica SP5 confocal 
microscope was used to image cells. B) HK-2 cells were again subjected to exogenous DNA stress with NCS, Dox, 
or CPT. The same control conditions were used as previous experiment. γH2AX and phospho-DNA-PKcs 
antibodies were used as primary antibodies to detect the DSB damage marker and active NHEJ repair, 
respectively. Secondary antibodies conjugated to the fluorescent probes, Rhodamine Red and Alexa Fluor 488 
were used to detect γH2AX and phospho-DNA-PKcs. Coverslips were mounted with Vectashield containing 
DAPI to detect nucleus. Scale bar: 10 µm. Cells were imaged with a Leica SP5 confocal microscope. 
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Section Thirteen: JADE1 and PRKDC/DNA-PKcs and DDB1 expression 
analysis utilizing TCGA RCC data 
 Our IP studies indicated that Jade-1 associated with DNA-PKcs and DDB1. 
However, we wondered if there were any transcriptional differences in these repair 
factors related to RCC. Therefore, we also examined expression analysis of DNA-PKcs 
(gene name: PRKDC) and DDB1 using the TCGA database. This resource has 
information regarding many renal cancer tumor samples as well as normal tissue samples 
from the same patients. We compared the expression levels of these two distinct DNA 
repair proteins compared to JADE1 expression levels in RCC samples compared to their 
normal counterparts. This data is represented as fragments per kilobase of transcript per 
million (FPKM) mapped reads. We found that, in the 464 samples examined, there were 
lower amounts of JADE1, PRKDC /DNA-PKcs, and DDB1 in cancer tissue compared to 
normal tissue. 12.2 vs 17.6 for Jade-1, 8.3 vs 10.3 for PRKDC/DNA-PKcs, and 122.1 and 
153.0 for DDB1. This reflects a ratio of less than one in tumor tissue for each gene, 0.695 
for JADE1 and 0.806 and 0.798 for PRKDC/DNA-PKcs and DDB1, respectively. A 
student’s t-test was performed to determine statistical significance of these differences, 
and it was found that all the transcripts are significantly reduced in expression in the RCC 
versus normal tissues. A p-value of less than 0.05 was deemed statistically significant 
when comparing the transcript levels between the two groups (Table 5). The samples 
were also divided in half into two categories: high JADE1- and low JADE1- expressing 
RCC samples. JADE1 expression was 15.3 in the high JADE1 and 7.9 in the low JADE1 
samples, with a two-fold change between the two groups. This difference in transcript 
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levels was statistically significant. Interesting, in these two groups PRKDC/DNA-PKcs 
expression levels were similar in the two groups, 7.0 in high JADE1 samples vs 6.8 in the 
low JADE1 samples, and this did not achieve significance. When DDB1 analysis was 
done in these two categories it was found that expression levels were 111.6 in high 
JADE1 samples and 97.8 in low JADE1 samples. DDB1 levels were low in low JADE1 
cancer samples and high in high JADE1 samples. Further evaluation with student’s t-test 
determined that these values were statistically significant (Table 6). In general, this 
assessment shows that there are transcriptional changes of DNA repair proteins that are 
taking place in RCC samples compared with normal tissue and that may depend on 
changes in JADE1 expression. Our laboratory had reported that JADE1 levels change in 
RCC samples compared to normal kidney tissue, but this new analysis reveals that DDB1 
message also changes in kidney cancer when samples are divided into categories based 
on JADE1 levels. 
Table 5. JADE1, PRKDC/DNA-PKcs, and DDB1 gene expression comparison between RCC vs its normal 
counterpart. 
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Table 6. PRKDC/DNA-PKcs and DDB1 gene expression comparison between high vs low JADE1 RCC groups. 
 
 
Section Fourteen: Evaluating NER 
Subsection One: Jade-1 and DDB1 binding interaction verification 
 The initial mass spectrometry analysis identified the major NER protein, DDB1 as 
a potential Jade-1 interactor. Moreover, there were seven unique spectra identified (Table 
3) from this analysis and so we sought to verify this association. 293T cells were used to 
overexpress a Flag-tagged DDB1 construct as well as a Myc-tagged Jade-1 construct. 
These were transfected either separately or together. We also used the appropriate empty 
vector plasmids and transfected these individually in another set of cells. MG132 was 
used to prevent protein turnover thus increasing the probability of detecting a binding 
interaction between proteins of interest. First, the transfection and proteasome inhibitor 
treatment efficiency were evaluated in the 293T samples. While no Flag- or Myc-tagged 
signal was detected in our lysates, there was a confirmation that the tagged Jade-1 and 
DDB1 protein were highly expressed. Moreover, the addition of MG132 showed the 
enrichment of the tagged proteins compared to the control-treated cells. This is visible in 
both immunoblots, which show a smeared effect in the lanes that were treated with 
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MG132 (Figure 23, lane 1 vs 2, lane 3 vs 4, lanes 5 vs 6). We used these lysates to 
perform co-immunoprecipitations using purified antibodies to pull down the tagged 
proteins. Flag conjugated agarose beads were used and Myc antibody with subsequent 
agarose bead incubation was done for the IPs. We ran 25 µg of WCLs along with the IP 
samples and detected the Flag-tagged DDB1 and Myc-tagged Jade-1 proteins using Flag 
and Myc antibody. Figure 13B shows that both Flag-DDB1 and Myc-Jade-1 were 
adequately pulled down in the IP. There seemed to be an enrichment of Flag-DDB1 with 
the control-treated cells IP. Immunoprecipitated Myc-Jade-1 levels did not increase as 
much in the IP (Figure 23B, lane 1 vs 2). The IP efficiency in the MG132-treated cells 
did not demonstrate an increase in amount of tagged proteins. However, for both co-IPs, 
there was good amount of interaction between Flag-tagged DDB1 and Myc-Jade-1. The 
Myc immunoblot shows that Flag IP was able to associate with most of the Myc-Jade-1 
protein (Figure 23B, lanes 2 and 5). On the other hand, while the Myc IP did bring down 
Flag-DDB1 there was not as much of this tagged protein bound to Myc-Jade-1 (Figure 
23B, lanes 3 and 6). Along with these co-IPs, control IPs were included to further support 
the binding between Myc-Jade-1 and Flag-DDB1. As previously stated, 293T cells were 
transfected with empty vector plasmids. When Flag-V0 was used Myc-Jade-1 as co-
transfected and when Myc-V0 was incorporated Flag-DDB1 was included. These cells 
were all treated with MG132 to enhance protein-protein interactions. When Flag antibody 
was used to detect either Flag-DDB1 or Flag-V0 there was no Flag signal in the cells 
without overexpressed, tagged DDB1 (Figure 23C, lanes 3-6). Likewise, this result 
occurred in the Myc immunoblot, there was visible Myc signal in the cells transfected 
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with Myc-Jade-1 plasmid, but none in the myc-V0 samples (Figure 23C, lanes 4-6). 
Moreover, there was no binding detected in these empty vector co-IPs. 
 As a follow up to these experiments, we wanted to assess the interaction between 
endogenous Jade-1 and DDB1. Untreated 293T cells were used to IP Jade-1 with DDB1 
antibody. As seen in Figure 23D, there was substantial pull down of the endogenous 
DDB1 protein when compared to the input sample. Even though we only loaded 25 µg of 
total protein for the input, we were able to detect naturally present amounts of DDB1 
(Figure 23D, DDB1 IB). Jade-1 also bound to DDB1 and with higher exposure, this 
signal was more pronounced. Also, with higher exposure of the Jade-1 blot we could see 
endogenous Jade-1 in the input lane as well (Figure 23D, Jade-1 IBs). When comparing 
the higher exposure Jade-1 input signal versus immunoprecipitated Jade-1 there seems to 
be good portion of the endogenous Jade-1 that associates with endogenous DDB1 (Figure 
23D, Jade-1input in higher exposure IB vs Jade-1 IP in lower exposure IB). These studies 
demonstrate that Jade-1 and DDB1 are binding partners. 
23A 
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Figure 23. Jade-1 interacts with DDB1.  
A) Confirmation of expression of transfected Flag-DDB1 and Myc-Jade-1. HEK 293T cells were co-transfected 
with myc-Jade-1S and Flag-DDB1. Co-transfection of Flag empty vector (Flag V0) and Myc-Jade-1S (Jade-1 
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short isoform) or Myc empty vector (Myc V0) and Flag-DDB1 was also performed. The cells were treated with 
DMSO or 10 µM MG132 overnight, and cell lysates were collected to verify expression of the constructs. First 
two lanes (left panels) show co-transfection of Flag DDB1 and Myc-Jade-1S while last four lanes (right panels) 
show empty vector counterparts with either Myc-Jade-1S (lanes 3 and 4) or Flag DDB1 (lanes 5 and 6). B) 
Transfected Flag-DDB1 binds transfected Myc-Jade-1The Flag-DDB1 and Myc-Jade-1S lysates were used for 
co-IP experiments using Flag (F) or Myc (M) antibodies were used to pull down target tagged proteins. Whole 
cells lysates were included in lanes 1 and 4, with DMSO or MG132 treatment, respectively. Immunoprecipitation 
and co-IP efficiencies were evaluated using either Flag or Myc antibodies. C) Control immunoprecipitations 
were performed with the MG132-treated cell lysates containing empty vector counterpart with either Flag 
DDB1 or Myc-Jade-1S. Lanes 1 and 4 show WCLs while other lanes show IPs with either Flag or Myc 
antibodies and no detection empty vector constructs being expressed or immunoprecipitated. At least 1 mg of 
protein was used for each IP and 25 µg WCL sample was used for input lanes. D) Endogenous DDB1 and 
endogenous Jade-1 interact. Endogenous DDB1 was immunoprecipitated from 293T lysates using DDB1 
antibody. DDB1 and Jade-1 protein were detected using DDB1 antibody and Jade-1 antiserum, respectively. 
Higher exposure of film was needed to verify endogenous Jade-1 expression in cells as shorter exposures did not 
show Jade-1, but did show Jade-1 and DDB1 association. At least 1 mg of protein was used for 
immunoprecipitation and 50 µg WCL sample was used for input. 
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Subsection Two: Jade-1 and DDB levels in UV-treated 293T cells   
 Along with these studies we also attempted to see if there was a change in Jade-1 
protein levels in the presence of UV damage. For this the exposure time to UV light was 
calculated. 293T cells were then placed in a tissue culture hood and subjected to either 
bright light or 10, 20, and 50 kilojoules per meter squared (kJ/m2) of UV light power. 
They cells were then lysed immediately following these conditions. In this study we did 
not see a change in Jade-1 levels after of damage. However, DDB1 levels did increase in 
both the 10 kJ/m2 and 20 kJ/m2 settings. DDB1 levels were 2.9 and 2.4 fold over the 
bright light exposed cells, respectively. At the highest light power, 50 kJ/m2, Jade-1 and 
DDB1 levels were around 50% below baseline levels (Figure 24). These results indicated 
to us that the cells were responsive to the UV damage. In brief, these experiments 
regarding Jade-1 and DDB1 show that there is a connection between Jade-1 and DDB1. 
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Figure 24. DDB1, but not Jade-1, protein levels increase in the presence of UV light in 293T cells. 
The 293T cells were placed in a tissue culture hood and subjected to UV irradiation for different lengths of time 
corresponding to 10, 20, and 50 kilojoules per meter squared (kJ/m2). Cells treated with 0 kJ/m2 were left under 
bright light conditions for the longest time point as a control conditions. Cell lysates were immediately collected 
and prepared for SDS-PAGE. Jade-1 antiserum and DDB1 antibody were used to detect protein levels for each 
condition. β-actin levels were used to normalize Jade-1 and DDB1. Densitometry analysis was performed using 
ImageJ. 
Subsection Three: Survival analysis of ccRCC patient data based on DDB1 expression 
levels 
 The TCGA ccRCC dataset was queried to investigate how DDB1 expression 
levels affected patient outcomes. The 463 samples were divided into two groups: low and 
high DDB1 gene expression. When median survival time was analyzed, there was a 
distinct difference in survival days between the two groups. The high expressing group 
had 354 days of median survival time while the low expressing group had 306 days. This 
was a difference of 48 days longer survival in those with higher transcript levels of 
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DDB1. Each individual’s survival from these groups were graphed as a Kaplan-Meier 
curve. These values were further evaluated using a log rank test and the p value was 
0.017 (Figure 25A). A p value of less than 0.05 signified that there was a statistical 
significance between these two groups.  
 A similar analysis was done with these samples and dividing them into a low and 
high PRKDC/DNA-PKcs expression groups. The median survival times were compared 
between the two patient categories and plotted as a Kaplan-Meier curve. Individuals with 
low PRKDC/DNA-PKcs expression levels the median length of survival was 316 days. 
For those with high PRKDC/DNA-PKcs transcript levels it was 339 days. This was 
difference of 23 days between days between the two groups, but there was no statistically 
significant difference between the two groups when analyzed via log-rank test (Figure 
25B). Censored data, which represent patient data only until the last recorded session, 
was also included in the survival curves. This censored data may have affected the 
prognosis of each group. The possibility remains that there would be a greater difference 
between survival times for the genes analyzed. For instance, there was not significance 
associated when comparing survival between high and low PRKDC/DNA-PKcs groups. 
If the high PRKDC/DNA-PKcs individuals, who did not have a recorded end date, 
resulted in having longer survival then there could be a significant correlation showing 
that higher PRKDC/DNA-PKcs levels correlate with better prognosis. 
In general these results suggest that higher transcript levels of DDB1 are 
beneficial for individuals with ccRCC as survival time is longer for these patients. This 
relates to the JADE1 data in which patients were categorized into low or high JADE1 
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expression levels (Table 6). Those with higher levels of JADE1, who have better a better 
prognosis in ccRCC, also have higher levels of DDB1, which was statistically significant. 
However, PRKDC/DNA-PKcs expression levels are not correlated with better outcomes 
in those with ccRCC. It is important to note, that changes in gene expression do not 
necessarily mean that this definitively impacts what is happening within the cell. The 
protein, which is the functional unit acting within the cells, likely has a greater 
contribution to signaling pathways and mechanisms that maintain cellular homeostasis. 
Of great relevance related to the studies presented here, Zheng et al. found that DNA-
PKcs protein levels are increased in ccRCC cell lines and patient RCC samples compared 
with HK-2 cells and normal tissues, respectively. Furthermore, DNA-PKcs activity was 
associated with mTORC2 pathway activation and HIF2α upregulation. Therefore, this 
study showed that DNA-PKcs overexpression contributes to RCC pathogenesis and 
suggests that targeting DNA-PKcs protein could interrupt disease progression. (Zheng et 
al., 2016). 
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Figure 25. Kaplan-Meier survival curves based on low and high DDB1or PRKDC/DNA-PKcs expression levels. 
A) DDB1 expression is significantly correlated with prognosis. There is greater median survival time, 354 days, 
with higher DDB1 expression versus 306 days with lower DDB1 expression levels, resulting in 48 more days of 
survival for high DDB1 expression patients. B) PRKDC/DNA-PKcs levels are not significantly correlated with 
prognosis. However, higher PRKDC/DNA-PKcs expression is associated with a trend toward longer survival 
time, 339 days, compared to individuals with lower PRKDC/DNA-PKcs levels who had a shorter median survival 
time, 316 days. RCC samples (n=463) were divided in Median High expression (n=231) and Median Low 
expression (n=232) for either DDB1 or PRKDC/DNA-PKcs. The analysis took into account censored data, which 
are individuals with no final survival time point recorded. Each censoring event is noted as a short vertical bar 
on the curve Log rank tests were used to compare the median survival days between the two groups; a p-value 
less than 0.05 indicates significance. Figures generated from TCGA data by Dr. Amit Mittal from the Cohen 
laboratory. 
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CHAPTER FOUR: DISCUSSION 
Section One: Conclusions 
Subsection One: Findings Overview 
Through these studies we have offered insight into a novel role for the renal tumor 
suppressor, Jade-1 in ccRCC, a disease which has limited treatment options at advanced 
stages. Jade-1 is involved in the DNA damage response system, specifically in the NHEJ 
and NER mechanisms, and this has been determined via the following ways: 
1) Through our initial immunoprecipitation efforts we identified a connection 
between Jade-1 and several DNA repair proteins and pathways. 
2) We verified the interaction between Jade-1 and the well-known DSB repair 
protein, DNA-PKcs. 
3) We primarily focused our experiments on the DSB repair pathway and 
discovered that Jade-1 is induced in response to DSB damaging agents, using multiple 
approaches and kidney cell lines.  
4) IF studies with the immortalized HK-2 cells provided further evidence that 
Jade-1 is implicated in DNA repair processes. Jade-1 co-localizes with the DSB-damage 
marker, γH2AX in cells treated with different agents. We also determined that the cells 
undergo active NHEJ repair by immunofluorescence for phospho-DNA-PKcs (serine 
2056); this signal also co-localizes with γH2AX. Furthermore, γH2AX dynamics differed 
between the parental si47 cells, indicating defective DNA damage signaling in the 
knockdown line. 
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5) When the HK-2 cells were subjected to DSB, the line with reduced JADE1 was 
less sensitive to NCS. Moreover, in colony forming assays we found that JADE1 
knockdown lines were able to grow more colonies after DNA damage. 
6) In DDB-1 related studies, we confirmed the interaction between Jade-1 and 
DDB1 via co-IP experiments with overexpressed and endogenous proteins. We also 
found higher DDB1 expression levels were seen in high JADE1 expressing RCC samples. 
Moreover, we saw that there was a survival advantage for patients who have high DDB1 
levels-individuals with this characteristic live longer than those with lower DDB1 levels. 
These results point to the direct role of Jade-1 in DNA repair through interaction 
with DNA-PKcs and DDB1. The proper regulation of these processes and the DNA 
damage response are extremely important in maintaining genomic integrity. As a renal 
tumor suppressor that is not completely lost in ccRCC, Jade-1, could be a key target for 
the treatment of this devastating disease. 
Subsection Two: Jade-1 connection to DNA repair pathways 
Our initial immunoprecipitation effort aimed to identify Jade-1 interactors that 
could reveal novel tumor suppressor functions for Jade-1. A number of proteins identified 
through mass spectrometry analysis were related the DNA damage response system 
(Table 3). Moreover, most of the processes identified by IPA were related to DNA 
maintenance (NHEJ, telomerase elongation pathway, mismatch repair) (Table 2 and 
Figure 12). These preliminary findings suggested that Jade-1 could be involved in DNA 
repair mechanisms. 
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The link to these pathways is significant, as it has been established that one of 
characteristics of many cancers is increased genomic instability (Negrini, Gorgoulis, & 
Halazonetis, 2010). Additionally, DNA repair pathways are dysregulated in many cancers 
(Jeggo, Pearl, & Carr, 2016). Molecular analyses of clear-cell renal cell carcinoma 
(ccRCC) have also shown that this tumor subtype has a high level of tumor heterogeneity 
and chromosomal translocations (Battaglia, 2012; Cancer & Atlas, 2013; Sato et al., 
2013). We focused our studies on DSB repair because of the potential direct contribution 
of this mechanism in ccRCC pathogenesis.  
Jade-1 was affected at the translational and transcriptional in the presence of DSB 
damage. In breast cancer cells, Jade-1 protein and mRNA levels increased when exposed 
to NCS (Wan, 2013). We investigated what role Jade-1 had in kidney cells and how these 
studies might be relevant for ccRCC. Similarly, we found that Jade-1 protein is induced 
in the presence of DSB damage, but decreased message level in 293T cells. The 
transformed 293T embryonic cells have normal Jade-1 levels and can react to exogenous 
DNA stressors. Jade-1 protein induction in these cells over time suggests that Jade-1 is 
important in mediating the cellular response to DSB damage (Figure 14A). Interestingly, 
JADE1 message levels seemed to decrease to about half of baseline levels after 24 hours 
of DNA damage (Figure 14B). This drop in transcript levels at this time point could just 
be counter-regulatory, due to increased levels of Jade-1 protein. Alternatively, the 
decrease in JADE1 message could be related to sustained presence of the drug and the 
initiation of cell death. Although Jade-1 protein may be involved in this process, there 
would be less of a need to create more protein at that point. Overall, Jade-1 protein 
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function may be more critical than transcript level changes when the cells is under 
genotoxic stress. 
We also tested the model ccRCC 786-O cells because they are adult epithelial 
renal cancer cells that are VHL-negative (Williams, Elliott, Stein, & Fraley, 1978). When 
these cells were evaluated, Jade-1 protein levels were not upregulated as high as in the 
293T cells that do express pVHL. The 786-O cells have low Jade-1 levels due to the 
absence of pVHL. Moreover, it is thought that cancer cells take advantage of the 
proteasome pathway to overcome the effects of tumor suppressor proteins, such as Jade-
1. Indeed, our lab has shown that Jade-1 levels increase substantially in renal cancer lines 
treated with MG132 (Zhou et al., 2005). These already low levels of Jade-1in the 786-O 
cell line may not be greatly increased under these conditions even in the presence of 
DNA damage. 
Our laboratory established that pVHL stabilizes Jade-1 and we sought to 
determine if the re-introduction of pVHL would influence Jade-1 levels when cells are 
subjected to DSB damage. We tested 786-O cells that either stably expressed a control 
empty vector or an HA-VHL construct, but we did not see Jade-1 induction in the cell 
lines as observed in the parental cell line (Figure 15B vs Figure 14C). pVHL may not be 
directly modulating Jade-1 levels in DSB damage, but is still important in DDR, as 
discussed below. 
We saw Jade-1 protein increases in physiologically relevant proximal tubule cells 
treated with NCS. However, Jade-1 induction was not as pronounced as it had been with 
either the 293T or 786-O cells. This subdued effect could be due to the ability of these 
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cells to actively pump drugs and other molecules out of the cell and into the extracellular 
environment. These differentiated cells normally function to maintain cellular 
homeostasis by removing wastes and toxins from the blood and regulating electrolyte 
balance via transporters (Inui, Masuda, & Saito, 2000; Nigam et al., 2015). It is possible 
that because of this pump activity there was a reduced effect of the NCS on Jade-1. 
Nevertheless, we observed that the cells respond to DNA damage even though this 
fluctuated over time (Figure 16A and B). 
Renal drug transporters and adequate drug concentrations could also be reasons as 
to why Jade-1 levels were not upregulated to the same degree when the HK-2 cells 
(parental and nonsi) were treated with either doxorubicin or cisplatin (Figure 18A and B). 
Although there seemed to be a slight increase in Jade-1 protein levels in these cells, the 
effect was less pronounced than expected. There were also fluctuations at the different 
time points in both situations. This had also occurred in the 786-O cells which should 
also have similar drug pump activity. The cells may react differently to different 
compounds as there are structural differences that could influence how the drug pumps 
interact with them. Another interesting aspect was the smear effect on Jade-1 with 
cisplatin treatment. Usually, the Jade-1 band is distinguishable and, at times, even 
appears as a doublet. In the doublet, the top band is thought to be a phosphorylated 
version of Jade-1 while the bottom band is the unmodified form. The Jade-1 band that 
appeared in the cisplatin-treated samples was not very discernable. This may represent a 
ubiquitination modification on Jade-1. Multiple bound ubiquitins would produce a larger 
molecular weight protein and would create a smeared, blurry effect on the immunoblot. 
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This modification might direct Jade-1 towards proteasomal degradation which may be 
due to the 50 µM cisplatin concentration. This could be a specific effect of cisplatin on 
Jade-1. In future research, lower concentrations of cisplatin could be tested to seek a 
more distinct Jade-1 band. 
In previous publications from our laboratory, Jade-1 was found throughout the 
cell, in the nucleus, cytoplasm and perhaps at the cell membrane. Since some of the 
potential Jade-1 interactors functioned in DNA repair, which would most likely occur in 
the nucleus, we expected to see elevated nuclear Jade-1 levels in our fractionation 
studies. This was not the case, however, and could be due to the fractionation protocol 
used (Figure 17A and B). We isolated cytoplasmic and nuclear lysates with buffers of 
differing salt concentrations, but we may have failed to isolate the proteins that were 
bound to the DNA. DNA-bound Jade-1 could be increased in the presence of DSB 
damage, and we would be able to see that there is an increase in Jade-1 in the nucleus if 
we tried other conditions to release proteins with strong DNA affinity. In support of this 
notion, we did see increased Jade-1 nuclear fluorescence in response to DNA damaging 
agents (Figure 22A, panels 2, 4, and 5). It is entirely possible that accumulation of Jade-1 
in the cytoplasm is a critical response to DNA damage. Jade-1 may have a role in the 
cytoplasm by acting on or with DNA repair proteins. As an example, DNA-PK has been 
found to have cytoplasmic function during DSB-induced damage. It is able to 
phosphorylate GOLPH3, a structural Golgi protein, which allows fragmentation of the 
organelle (Farber-Katz et al., 2014). Future work could be done to discover if Jade-1, 
along with DNA-PKcs, has any effect on this process. 
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The cellular response to DNA damage occurs very rapidly. Therefore, we 
investigated Jade-1 levels at earlier time points in the HK-2 line. There was increased 
abundance of Jade-1 with DSB damage at around 30 minutes of treatment, and this 
extended into 90 minutes (Figure 16B). These findings indicated that Jade-1 might be an 
early responder to DNA damage and potentially influence DSB repair mechanisms. 
In brief, this set of experiments indicated the potential role Jade-1 in DNA repair. 
There are other major DNA repair mechanisms that were not explored. Jade-1 may be 
associated with a number of pathways in order to maintain genomic stability and are 
potential avenues to pursue besides DNA DSB repair. Our protein data are supported by 
work done by Wan et al., who demonstrated an increase in Jade-1 levels with NCS 
treatment. However, our mRNA analysis differs from theirs, in both the 293T and 786-O 
cells, as they determined that Jade-1 transcript levels also rise with DNA damage (Wan 
et al., 2013). Importantly, in their studies, they were assessing Jade-1L isoform and 
concluded that Jade-1 had a pro-tumorigenic influence in breast cancer. It is worthwhile 
to consider that the isoforms may have opposing roles in the DNA damage response 
system. Experiments to assess the level of Jade-1L protein and mRNA transcripts could 
be performed in these cells. Moreover, there could be cell-specific differences that are 
represented in these findings with regards to the role of Jade-1 in DNA repair. 
Additionally, our experiments indicate that Jade-1 induction may be pVHL-independent 
and that perhaps pVHL is not implicated in the Jade-1 mediate response to DSBs. 
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Subsection Two: Jade-1 interacts with DNA-PKcs 
The interaction between Jade-1 and newly-identified binding partners could be 
directly influencing DNA repair mechanisms. We found that Jade-1 binds the DNA-
dependent protein kinase catalytic subunit (Figure 13). Our studies predominantly show 
that Jade-1 binds either a 240 or 170/180 kDa DNA-PKcs fragment. There was also an 
interaction between Jade-1 the full length, 470 kDa DNA-PKcs product in the presence of 
the DSB damaging agent, NCS. Interestingly, the DNA-PKcs 170/180 kDa cleavage 
product, which is the C-terminal region, contains the kinase domain (Song et al., 1996). 
The DNA-PKcs fragment associated with Jade-1 most likely contains the kinase domain. 
Thus, Jade-1 may interact with the kinase domain DNA-PKcs to modulate its enzymatic 
activity during DSB repair. In support of this relationship, previous studies in our 
laboratory demonstrated that Jade-1 binds the catalytic domain and regulatory tail of 
another serine/threonine kinase, AKT1. Jade-1 also diminished AKT1 phosphorylation at 
serine 473, a key activation site, indicating that Jade-1 inhibits AKT1 activity (Zeng et 
al., 2013). Moreover, S473 phosphorylation is promoted by DNA-PK (Bozulic et al., 
2008), suggesting that Jade-1 may inhibit this DNA-PK activity. Other 
immunoprecipitations can be done with separate, overexpressed constructs of both DNA-
PKcs and Jade-1. This will elucidate which regions of each protein are in important for 
their interaction. Additionally, in vitro kinase or ubiquitination assays would determine if 
there is any enzymatic activity occurring between the proteins. 
Furthermore, DNA-PKcs has a distinct fragmentation pattern which has been 
associated with cells undergoing apoptosis. Bharti et al. determined that caspase 3 is 
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responsible for cleaving DNA-PKcs into approximately 240, 150, and 120 kDa 
fragments. This group also demonstrated that the 240 kDa fragment is phosphorylated 
and catalytically active (Bharti et al., 1998).It is likely that apoptosis is happening in our 
immunoprecipitation studies and Jade-1 may bind more readily DNA-PKcs fragments 
during this process. Although we did not explore this further, it is possible to assess, in 
additional experiments, the extent of cell death in the cell populations. This could be done 
through cell sorting analysis and immunoblot studies. 
As Jade-1 is known binding partner and an E3 ubiquitin ligase for β-catenin, we 
wished to determine if there might be a similar relationship between Jade-1 and DNA-
PKcs. Therefore, we performed co-immunoprecipitations in the presence of proteasome 
inhibitor MG132. We verified that there was a specific interaction between Jade-1 and 
DNA-PKcs since β-catenin did not bind to DNA-PKcs. However, the interaction between 
Jade-1 and DNA-PKcs was not augmented by MG132, nor did DNA-PKcs protein 
abundance increase. This suggests that proteasomal degradation does not influence 
binding and that they associate regardless of this biological process taking place. 
Subsection Three: Jade-1 is present at active sites of DSB damage 
The binding between Jade-1 and DNA-PKcs indicated that Jade-1 may be found 
at DSB damage sites. In support of this, our immunofluorescence studies show that Jade-
1 co-localizes with γH2AX. This histone is a phosphorylated H2A variant that gets 
incorporated into sites of DSB damage (Fernandez-Capetillo, Lee, Nussenzweig, & 
Nussenzweig, 2004). There were multiple co-localizing foci that appeared in the 
proximal tubule cells when treated with NCS, doxorubicin or CPT compared to control 
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conditions (Figure 22A). There was also a noticeable increase in Jade-1 brightness, 
although not quantified, which suggests that fluctuations in levels of Jade-1 are taking 
place in the subcellular compartments. These observations support the immunoblot data 
that Jade-1 protein levels increase in response to agents that induce DSBs. 
There may be stabilization of Jade-1 in the presence of damage through post-
translational modifications. Studies done in our laboratory show that Jade-1 is stabilized 
by pVHL. pVHL may help to stabilize Jade-1 when different types of DNA damage (not 
DSB damage) take place in normal kidney cells, and this may be diminished when pVHL 
is lost in kidney cancer. Additionally, there could be other proteins, besides pVHL, that 
help stabilize Jade-1 in the presence of genetic stress. Another possibility is that 
translocation of Jade-1 could also be occurring in cells that are exposed DNA damage. 
Earlier time points would be necessary to see if there were gradual increases in Jade-1 
brightness. 
DNA-PKcs is most well-known for its role in DNA repair through NHEJ. 
Phosphorylation of DNA-PKcs at serine 2056 represents active DSB repair at a damage 
site. We examined this signal and confirmed that NHEJ was active with DSB damage 
treatment in our HK-2 cells. There are also other known DNA-PKcs phosphorylation 
sites that appear throughout the NHEJ repair process. Jade-1 may influence these 
modifications and this could provide more information regarding how far in the process 
Jade-1 remains at damage sites. More studies can be done using the knockdown cells to 
see if there are differences in DNA-PKcs modification when Jade-1 is reduced. 
Moreover, other known DDR proteins also co-localize with γH2AX. Live cell imaging 
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would help visualize Jade-1 and other repair factors moving throughout the cell. There 
may be a certain time point where there is peak co-localization between Jade-1 and 
γH2AX or other DDR proteins. 
Immunofluorescence was also used to test whether Jade-1 differences had a more 
direct impact on DSB repair in the parental and stable proximal tubule cells. γH2AX 
fluorescence was done to examine repair dynamics. When repair is complete the absence 
of this DSB damage marker indicates damage resolution. We analyzed γH2AX signal 
between the parental and the si47 knockdown cell line and discovered that even without 
DSB damage treatment there was a difference in γH2AX between the two lines. This 
showed that cells having diminished Jade-1 levels as the only difference had abnormal 
DNA damage signaling. The decreased γH2AX-positivity could mean that these cells are 
able to repair their DNA at a faster rate, and so there is a lower level of the DSB damage 
marker. Furthermore, this might be the case if NHEJ is the preferred mechanism to 
overcome damage, since this process is completed in approximately 30 minutes 
compared to 7 hours with HR(Mao, Bozzella, Seluanov, & Gorbunova, 2008). This 
supports other assays where JADE1 knockdown cells tend to fare better with DSB 
damage (discussed below). 
In summary, we found that both Jade-1 and DNA-PKcs are found at sites of DSB 
damage through their partial co-localization with γH2AX foci. We also visualized an 
increased Jade-1 signal in cells treated with DNA damage agents, which indicates that 
Jade-1 responds promptly to DSBs. Similarly, phosphorylated DNA-PKcs signal verified 
the DSB repair activity was taking place in these cells. This indirectly supports the idea 
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that Jade-1 regulates NHEJ through DNA-PKcs. The abnormal γH2AX dynamics in HK-
2 cells also shows that the loss of Jade-1 alone has an impact on DNA repair activity. 
Subsection Four: Jade-1 knockdown affects survival and colony formation after DNA 
damage 
We determined if differences in Jade-1 levels affected cell survival through 
sensitivity and colony forming assays (CFAs). In these assays we used the stable HK-2 
cell lines as they have sustained knockdown of Jade-1 message and consequently reduced 
Jade-1 protein levels. Sensitivity assays were done to explore the effects Jade-1 had on 
kidney cell viability after DSB damage. These experiments also provided an indication as 
to whether there might differences when either both Jade-1 isoforms were absent or 
solely the short isoform. We found that the HK-2 si47 cells, which have diminished Jade-
1S protein, are less sensitive to neocarzinostatin treatment compared to the three other 
cell lines (Figure 19). The ability of the si47 cells to survive NCS can be attributed to the 
absence of the short isoform, acting as a tumor suppressor and negatively regulating 
NHEJ repair. This would permit greater survival because the cells can manage genetic 
stress more promptly, albeit with increased likelihood for DNA aberrations. This survival 
outcome is preferred, as it would allow the cell to keep replicating. 
Interestingly, the absence of both Jade-1S and Jade-1L isoforms (si25 line) may 
signify that the isoforms act in opposing manners, where the Jade-1L might act to 
promote survival while Jade-1S might inhibit viability. However, if both are absent this 
could be detrimental as there is no factor (Jade-1L) that would help with proper positive 
regulation of cellular processes relating to DNA damage. At the highest concentration 
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used (500 nM), viability of all cell lines had dropped to 10% or less. This signifies that 
there is a range where damage levels are low enough to overcome, but there is a “point-
of-no-return,” at which the cells undergo cell death due to overwhelming stress. Further 
studies could be done to determine how the two major Jade-1 isoforms are independently 
involved in DNA damage. Another cell line could be created to specifically knockdown 
Jade-1L and compare the results to the si47 line. 
We evaluated differences in the cells’ ability to recover from damage and 
proliferate as single colonies through CFAs. We separated the cell lines into two 
categories: parental and nonsi cells with baseline JADE1 versus si25 and si47 with 
JADE1 knockdown. The group with normal Jade-1 levels did not form as many colonies 
as the group of cells with JADE1 knockdown (Figure 20 and Table 4). Although both 
JADE1 knockdown lines seemed to have a survival advantage over the JADE1 baseline 
cells, the si25 cells fared somewhat better than the si47 line. It is possible that another 
repair mechanism is compensating for the absence of the two Jade-1 isoforms, and this 
allows for greater colony formation. The difference in survival between the knockdown 
cell lines could also be due to the effect of Jade-1S on apoptosis. Jade-1S presence 
increases cleaved PARP levels as well as downregulates anti-apoptotic Bcl-2 protein 
levels when Jade-1S is expressed in renal cancer cells (Zhou et al., 2005). The absence of 
Jade-1S contributing to apoptosis may account for the increased colony number in the 
si25 cells. Overall, these data show that cells with reduced levels of Jade-1 that are 
subjected to DNA damage have an increased capacity to survive and grow. A similar 
observation has been made previously that when the MSH2 mismatch repair protein is 
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lost, the cells exhibit increased survival in response to DNA damage(de Wind et al., 
1995). 
Alternatively, the timing of repair may be a factor, as NHEJ is a faster process 
than HR. Thus, the way these colony-forming assays are designed may favor survival 
through NHEJ repair over HR. The cells are seeded at a low density (in a large space) and 
the need to overcome these suboptimal surroundings is crucial. The cells have to operate 
quickly in order to survive. The cells would proceed with the best resources available to 
recover and proliferate after DSB damage. This would likely be through enlisting NHEJ 
repair. On the other hand, the experimental setup in the sensitivity assays cells are found 
in a different environment. The cells have to cope with stress in a short time period and, 
while some may survive, others undergo apoptosis in these conditions. Follow up studies 
to determine how Jade-1 influences timing of DSB repair would be to use specific GFP 
constructs in human fibroblasts with JADE1 knockdown. When the restriction enzymes, 
Sce-I or Hind III are expressed they create DSBs that can only be repaired through NHEJ 
or HR. These experiments could inform us if more NHEJ repair is occurring without 
Jade-1 or more HR takes place with Jade-1, which is what we would expect. 
To evaluate the clinical relevance of DNA repair proteins in RCC we used TCGA 
data to explore how PRKDC/DNA-PKcs and DDB1 mRNA levels differed between 
normal and tumor tissues. In addition, the data were categorized into low vs high JADE1 
levels to compare expression levels of these factors. The TCGA analysis revealed that 
there are transcriptional changes occurring in RCC of DNA repair factors (Table 5 and 
6). These decreased expression levels of PRKDC/DNA-PKcs and DDB1 may be related 
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to the needs of the tumor compared to that of normal kidney cells. Perhaps, in normal 
cells or early on in tumor development, when cells are excessively proliferating, there is a 
greater need to have repair factors available to maintain genetic stability. However, over 
time, this would be detrimental, even for cancer cells that are always trying to survive. 
The transcripts that are negatively impacting that objective would need to be 
downregulated. Since JADE1 transcription, and consequently, translation are low at 
advanced cancer stages, the decrease in DNA-PKcs would not interfere with cancer 
progression. This is in line with an aspect of mutator phenotype hypothesis (discussed 
later), which is the deterrence of this increased mutations as disease progresses. This 
impedes cells from arriving at a mutational load that would counter cell survival. DDB1, 
which decreases as the tumor progresses and has lower expression in low JADE1 
expressing tumors, may play more of a tumor suppressor role and might act in 
conjunction with Jade-1 to help manage genetic aberrations. It is possible that Jade-1 
promotes DDB1 expression, and as the cancer progresses, and Jade-1 levels diminish then 
DDB1 expression is downregulated. Further experiments can be done to test whether 
DDB1 transcripts decrease without Jade-1. 
To summarize, we found that kidney cells with low Jade-1 levels survived better 
in both sensitivity and colony forming assays. This provides evidence that Jade-1 is 
influencing DSB repair and this could be through regulation of NHEJ. There were also 
changes in PRKDC/DNA-PKcs and DDB1 expression in RCC samples. These changes 
reveal that DNA damage repair proteins are regulated at the transcriptional level in RCC. 
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Furthermore, just as Jade-1 transcript levels are decreased in RCC, DDB1is also reduced 
as RCC progresses and this may be due to the transcriptional function of Jade-1. 
Subsection Five: Jade-1 and DDB1 studies 
The connection of Jade-1 to NER, although not studied to the same extent as 
DNA-PKcs. We observed a strong association between overexpressed Jade-1 and DDB1 
(Figure 23B). This was in contrast with our DNA-PKcs studies where it was challenging 
to detect Jade-1 interaction in DNA-PKcs IPs. Interestingly, the interaction existed even 
without DNA damage suggesting that normal Jade-1-DDB1 binding may be related to 
other cellular roles that are unrelated to maintaining genetic stability. This IP data also 
showed that there might be some influence of the proteasome on the Jade-1-DDB1 
interaction (Figure 23B, lanes 4-6). Further in vitro ubiquitination assays with purified 
proteins could elucidate if there are modifications on either protein as they both have 
potential ubiquitinating activity. 
We also attempted to induce DNA damage with UV irradiation and evaluate Jade-
1 levels. However, we were only able to detect DDB1 protein induction, and not Jade-1 
upregulation (Figure 24). Perhaps another approach should be used to see if this would 
stimulate Jade-1 protein levels. Some drugs, such as mitomycin C (MMC) can activate 
NER, but may also enlist other repair mechanisms (Lee, Park, Ciccone, Kim, & Lee, 
2006). If Jade-1 levels remain unchanged, there could still be influences on DDB1 or 
NER activity with Jade-1 that is readily available. Immunofluorescence experiments 
could also support Jade-1 and DDB1 association. HBO1 phosphorylation and H4 
acetylation changes can also be examined, as these are known responses to UV 
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irradiation (Matsunuma et al., 2016; Niida et al., 2017). Also, as both Jade-1 and DDB1 
are found at replication origins, this could be explored further. These proteins could be 
interacting to influence cell cycle progression, even without DNA damage. DDB1 may 
also regulate Jade-1 transcriptional activity. Luciferase reporter assays would be useful to 
find out if there are any changes when DDB1 expression is interrupted. 
The TCGA data were examined again to determine prognosis for patients with 
different expression levels of DDB1 or PRKDC/DNA-PKcs (Figure 25). Previously, the 
RCC data was categorized into low and high JADE1 expression groups. This time, 
however, the data were divided into low vs high expression levels of each DNA repair 
factor. This analysis revealed that higher DDB1 expression is associated with longer 
patient survival, which suggests that DDB1 presence may impede RCC. PRKDC/DNA-
PKcs did not seem to have a significant correlation on survival, but there was a trend 
toward greater survival with decreased levels as well. 
Section Two: Genomic stability in ccRCC 
Subsection One: RCC and the mutator phenotype 
CcRCC is the most prevalent RCC subtype and is impacted by genetic stability. 
The most frequently mutated gene in both hereditary and sporadic ccRCC is VHL. This 
gene lies on the short arm of chromosome 3 which is frequently lost and is thought to be 
a driver mutation for cancer pathogenesis. Recent research has demonstrated that pVHL, 
the VHL product, has a part in the DNA damage response network and supports DNA 
stability. 
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The mutator phenotype hypothesis explains the higher amounts of mutations in 
cancer cells vs normal cells. The mutator phenotype is acquired early on in oncogenesis 
and involves the alteration in a gene that affects genomic integrity. Genetic diversity is 
increased, through mutations, and permits cancer cells to promptly adapt to various 
conditions, even build resistance before expose to a drug. This quality is also the reason 
for the decreased mutation rate as cancer progresses. This is because increased mutations 
could yield a negative result for a cancer cell (Loeb, 2001, 2016). Targeting this 
characteristic can potentially deter tumor progression since there must be a balance of 
mutation acquisition as there is still a risk that a change can be deadly to cancer cells. If 
the mutational rate can be attenuated then disease progression can be delayed 
substantially, increasing the life expectancy of patients (J. Prindle, J. Fox, & A. Loeb, 
2010). The mutator phenotype is a likely situation that occurs in ccRCC, this type of 
cancer has a high degree of intratumoral heterogeneity. 
Subsection Two: The role of pVHL in the DDR 
 The inactivation of VHL/loss of pVHL contributes to RCC tumorigenesis, 
which makes it a likely candidate that initiates the mutator phenotype in this disease. 
Importantly, pVHL binds to and stabilizes p53, an important transcription factor that 
regulates the cell cycle and promotes apoptosis if DNA damage is too severe. p53 
degradation is inhibited when it interacts with pVHL and increases p53’s transcriptional 
capabilities. As a result, expression of apoptotic and cell cycle arrest genes are induced. 
This is enhanced in the presence of the DSB-inducing agent, Adriamycin (doxorubicin). 
Thus, pVHL regulates DSB damage response through p53 (J. S. Roe et al., 2006). Later 
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studies determined that Chk2, another kinase that is activated by DSB damage and 
modifies pVHL at serine 111. When pVHL is phosphorylated at this site this enables 
recruitment of p53 co-activators p300 and TIP60 to target genes (J. S. Roe et al., 2011). 
Interestingly, although TP53, the gene that encodes p53, is highly mutated in many 
cancers, this is not true for RCC tumors. Additionally, cancers such as clear cell ovarian 
cancer, medulloblastoma, and Wilms’ tumor are other types that have infrequent TP53 
mutations (Coppes, Sexsmith, & Yeger, 1994; Iii et al., 1991; Shih-Chu Ho et al., 2001). 
This supports the idea that the lack of another tumor suppressor gene substitutes for TP53 
mutations and this can permit disease pathogenesis. Thus, in patients with ccRCC, VHL 
inactivation disrupts proper DNA damage response, even when functional p53 remains 
present in renal cancer cells. 
More recently, Metcalf et al. reported that pVHL is ubiquitylated at K63 by 
SOCS1; however, this does not result in pVHL turnover. Instead,HRR is attenuated and 
DSBs remain present in cells (Metcalf et al., 2014). Another study which further 
supported pVHL’s connection to DSB repair found that 786-O cells had decreased 
expression of genes related to homologous recombination. The cells were also more 
sensitive to PARP-inhibitors and a follow-up analysis of human renal carcinoma samples 
revealed decreased levels of HR and MMR transcripts  in VHL-null tissues (Scanlon et 
al., 2017). 
With regards to other types of repair pathways, Schoenfeld et al. reported a 
relationship between pVHL, cell cycle inhibitors, and apoptotic effectors. When 786-O 
cells were exposed to UV light there was increased cell death due to the degradation of 
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p21WAF1/cip1 and p27, which upregulated cell proliferation and led to increased levels of 
pro-apoptotic factors. On the other hand, VHL-positive 786-Os had diminished anti-
apoptotic Bcl-2 and Bcl-xL abundance, indicating the pVHL was protective with UV 
exposure (Schoenfeld et al., 2000). This was one of the earliest studies that linked pVHL 
to the DNA damage response system. 
Subsection Three: Other ccRCC relevant genes affecting genetic integrity 
Further support for VHL, as well as other highly mutated genes that impact 
genetic integrity, is presented in an abstract by Pilie et al. They reported that double 
mutant VHL/SET domain containing protein 2 (SETD2) renal proximal tubule epithelial 
cells (RPTECs) and mouse embryonic fibroblasts (MEFs) with biallelic VHL loss and 
monoallelic SETD2 had defective HRR and increased NHEJ activity. Another significant 
finding was the assessment for level of mutational burden in early ccRCC samples. 
Whole exome sequencing (WES) of 11 ccRCC samples tested had around 100 
mutations/tumor and there was no overlap besides VHL inactivation. Overall they 
concluded that ccRCC acquired a mutator phenotype early on in oncogenesis and there 
was a dependence on error-prone repair (Pilie et al., 2017).SETD2 is histone modifier 
that is responsible for histone H3 trimethylation at K36. SETD2 was found to be required 
for DSB repair by HR. Mutant SETD2 in renal cancer cells failed to activate and induce 
p53 (Carvalho et al., 2014). 
The polybromo 1 (PBRM1) gene is lost in ccRCC. Espana-Agusti and colleagures 
investigated the effects of both Vhl and Pbrm1 deletion and found that replication stress 
was induced and in Vhl-deficient primary MEFs. This replication stress was attributed to 
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prolonged fork stalling and diminished fork progression. The cells also had decreased 
amounts of RAD51 and RPA32, which are important in replication fork response. 
Conditional tissue-specific Vhl-/-, Pbrm1-/-, and Vhl-/-; Pbrm1-/- mice were also generated 
to examine DNA damage in renal tubules. There was increased damage to these 
structures and cell cycle attenuation in Vhl-/- mice after treatment with MMC, which 
causes replication fork stalling. Meanwhile, the double mutant mice did not display 
replication stress and decreased γH2AX foci found at heterochromatin. PBRM1 is a 
component of the polybromo-associated BRG1-associated factor (PBAF) chromatin-
remodeller complex, which can modify histone H3 at lysine 9, a marker of 
heterochromatic areas in the nucleus. Pprbm1 loss or treatment with a lysine methylase 
inhibitor diminished trimethylated histone H3 lysine 9 (H3K9me3) and sensitivity to 
MMC. Overall, Pbrm1 deletion seemed to relieve replication stress through its influence 
on chromatin structure, conferring a survival advantage to cancer cells (Espana-Agusti, 
Warren, Chew, Adams, & Matakidou, 2017). 
Subsection Four: DNA-PKcs in RCC 
Several studies demonstrate the contribution of DNA-PKcs to cancer 
pathogenesis (Goodwin & Knudsen, 2014). Research from Zheng and colleagues strongly 
supports the pro-tumorigenic impact DNA-PKcs may have in RCC. They found that 
human RCC samples expressed high levels of DNA-PKcs, at the protein and message 
level, when compared to normal kidney tissue. This is was also seen in renal cancer cells 
lines, A648 and 786-O. Furthermore, when DNA-PKcs was inhibited via drugs or 
through shRNA/siRNA-mediated knockdown, there was a reduction in cell proliferation, 
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viability and clonogenicity in renal cancer cells. This group also found that DNA-PKcs 
associated with mTORC2 complex proteins, mTOR, Rictor and SIN1 and that AKT 
phosphorylation at serine 473 was diminished with DNA-PKcs knockdown. HIF2α, 
which is implicated in RCC pathogenesis, was downregulated when DNA-PKcs was 
interrupted in 786-O cells. They verified these results with in vivo studies in nude mice. 
They found that with either small molecule inhibition or DNA-PKcs knockdown 
xenograft tumors grew more slowly than shRNA control xenografts. Once again, they 
saw decreased levels of AKT phosphorylation and HIF2α in their experimental 
conditions (Zheng et al., 2016). 
Early work on DNA-PKcs showed that it has several phosphorylation sites and 
that there are two major clusters on the catalytic subunit (Douglas et al., 2002). These are 
targeted either by the enzyme itself or ATM and ATR, the other major DNA damage 
response kinases. Moreover, inactivation of DNA-PK via autophosphorylation of the 
catalytic subunit allows DNA-PK to loosen from the DNA and proceed with end 
processing (Chan & Lees-Miller, 1996). However, if there are defects in phosphorylation 
dynamics then DSBs persist in the cell (Cui et al., 2005; Uematsu et al., 2007). 
Importantly, AKT1 is an activator of DNA-PK, and DNA-PK also targets AKT1 at serine 
473 (Bozulic et al., 2008; Feng, Park, Cron, Hess, & Hemmings, 2004; Toulany et al., 
2012). Thus, these two kinases are positive regulators for cell survival and inaccurate 
DNA repair. These findings are significant as our laboratory demonstrated that Jade-1 
modulates AKT1 phosphorylation status and activity. In the research presented here we 
show that Jade-1 binds DNA-PKcs and this may be in the C-terminal region where there 
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the catalytic domain lies. Jade-1 may potentially be regulating DNA-PKcs activity by 
interacting with this area. 
Another link to renal cancer is the response of DNA-PK to oxygen levels. DNA-
PK is also have a prominent role hypoxic conditions. The holoenzyme is activated in low 
oxygen conditions as opposed to DSBs and this was related to histone modification. 
H3K14 acetylation increased in the presence of 0.1% oxygen. However this effect was 
diminished when anacardic acid, a HAT inhibitor reagent was used. Interestingly, there 
was an increase of HIF1α, but not HIF2α, protein in DNA-PKcs proficient cells in a low 
oxygen environment. As functional readout of HIF1α accumulation, Glut1, a downstream 
gene target, was also upregulated in long-term hypoxic conditions (Bouquet et al., 2011). 
The work from this group connects hypoxia, which a common occurrence as a tumor 
develops, and gets resolved once the cells adapt to this stress with intact DNA-PKcs 
activity. It provides evidence that DNA-PK would drive oncogenesis in situations low 
oxygen surroundings, or, in the case of ccRCC “pseudo-hypoxic” conditions. 
Subsection Five: The role of Jade-1 in DNA repair 
 As a renal tumor suppressor, Jade-1 may also be playing a critical role in 
regulating DNA repair processes. Until recently, the first connection between Jade-1 and 
the DDR was made by Wan et al. Both Jade-1 protein and mRNA levels were 
upregulated with NCS. Moreover, Jade-1’s histone acetylation activity was implicated in 
DSB damage in breast cancer cells. Our work detailed here shows that Jade-1 influences 
DNA repair in the kidney, where Jade-1 is highly expressed. 
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Both full-length DNA-PKcs and a breakdown product of either 240 or 170/180 
kDA interact with Jade-1. Jade-1 may influence the status of critical autophosphorylation 
site on DNA-PKcs such as serine 2056 or threonine 3950, which is found in this C-
terminal region. This hypothesis is being tested in our laboratory. The HK-2 cells are 
being tested for differences in phosphorylation levels of DNA-PKcs at serine 2056 in 
response to changes in Jade-1 and DNA DSBs. Additional experiments could also 
explore whether any other DNA-PKcs phosphorylation sites are affected by changes in 
Jade-1 levels. As mentioned in the previous section Jade-1 also diminished AKT1 
phosphorylation suggesting that Jade-1 modulates AKT1 activity. Thus, in addition to the 
direct regulation of DNA-PKcs, Jade-1 may indirectly inhibit DNA-PKcs by inhibiting 
AKT1. 
Jade-1 also binds DDB1, which mediates the degradation of HBO1 (along with 
DDB2) during UV light damage (Matsunuma et al., 2016). HBO1 is known Jade-1 
interactor that enables histone H4 acetylation (Doyon et al., 2006; Foy et al., 2008). The 
cooperation between Jade-1 and HBO1 is essential for DNA replication licensing at 
origins (Miotto & Struhl, 2010). The CRLDDB2 ubiquitination complex targets 
phosphorylated HBO1 at replication origins exposed to UV irradiation. This impedes cell 
proliferation when damage is present. Jade-1, in conjunction with HBO1, may aid in 
preventing cell cycle progression under DNA stress. Additionally, HBO1 is recruited to 
CPD sites, which facilitates DNA access to the NER machinery to properly repair DNA 
(Niida et al., 2017). Jade-1 may be recruited to these sites and specifically interact with 
DDB1 to enable the NER process. 
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Taken together, these studies provide strong evidence that the DNA damage 
response network is impacting RCC pathogenesis. The major renal tumor suppressor, 
pVHL, promotes DNA stability. Jade-1, as another tumor suppressor, may have multiple 
roles depending on the extent of DNA damage. It is possible that, in low level damage 
conditions in the cell, Jade-1 may be regulating DNA repair processes. In the case of 
DSB repair, Jade-1 may be negatively regulating DNA-PKcs to enable a decision towards 
HR. The work detailing DNA-PKcs levels in RCC support our hypothesis that Jade-1 
would act to counter the error prone NHEJ is process that is dysregulated in ccRCC. 
However, if there is an overwhelming level of damage then the cell would a make a 
decision towards cell death and Jade-1 may be involved in that process. Thus, Jade-1 may 
function to regulate both NHEJ and NER as well as the apoptotic cell death pathway. 
Subsection Six: Model 
 Based on the past and present findings we have developed a basic model of 
ccRCC disease progression with regards to pVHL and Jade-1 in the DNA damage 
response system. In normal kidney cells, these renal tumor suppressors are available to 
properly regulate pathways needed for normal growth and DNA maintenance. If there is 
DNA stress, pVHL can stabilize p53 while Jade-1 navigates to damage sites. The cells 
are able to adequately overcome these situations and continue functioning as usual 
(Figure 26A). 
Unfortunately, VHL loss would facilitate genetic instability, creating a mutator 
phenotype, and an individual may develop RCC. Once both VHL alleles are mutated, this 
allows the HIF transcription factors to upregulate the expression of a number of genes 
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that promote an environment where cell growth can be sustained. New blood vessels can 
form to bring more nutrients to the kidney while genes important for energy production 
are upregulated. Cells are stimulated to proliferate quickly and extensively in this 
favorable environment. However, this overactive cell replication also increases genetic 
stress due rapid growth. Excessive cell division would increase the number of mutations 
as well as the risk that DNA lesions would not be adequately repaired. Some acquired 
mutations could further drive disease progression. 
In this scenario, DNA damage signaling pathways and repair mechanisms might 
be constantly active to overcome genetic instability as best as possible. It is likely that 
DSB repair mechanisms would be one of the most critical processes used by these cells, 
especially non-homologous end-joining. NHEJ would be the preferred mechanism as 
repair components are readily available for recruitment to damage sites. HR would be 
secondary to NHEJ in order for cells advance through division (Figure 26B). Moreover, 
Jade-1, which would negatively regulate this error-prone process, and/or enable more 
accurate repair, might be unable to do so due to its downregulation at the transcriptional 
or translational level in cancer cells. 
As ccRCC develops, diminished Jade-1 levels would allow NHEJ to proceed and 
create greater genetic instability. This increases the probability that tumor cells achieve 
metastatic potential early on and allow the cells to spread beyond the kidney. However, if 
a small molecule were developed to increase Jade-1 levels then DNA-PKcs activity could 
be inhibited, thus promoting homologous recombination repair in the tumor cells. These 
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changes would promote cell death, shrink tumor size, and decrease mutations that lead to 
aggressive disease (Figure 26C). 
These studies have furthered our understanding about how Jade-1 might be inhibiting 
tumorigenesis in kidney cells. The sustained presence of renal tumor suppressor Jade-1 
might be critical in deterring the progression to kidney cancer when pVHL is lost. 
26A
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Figure 26. Model depicting roles of pVHL-Jade-1 in DNA repair in normal, RCC, and drug treatment 
conditions. 
A) In normal kidney cells pVHL interacts with and stabilizes Jade-1, allowing it to negatively regulate error-
prone NHEJ repair and favoring HR. Jade-1 would also influence NER through its connection with DDB1. Cells 
undergo more accurate DNA repair, which maintains genetic stability, and cells grow as usual. B) When VHL is 
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inactivated, pVHL is lost thus increasing Jade-1 turnover. In this setting, the increased gene expression of 
factors involved in angiogenesis, erythropoiesis, and metabolism creates an ideal environment for increased cell 
proliferation. As there is active replication, there is also a higher probability that DNA lesions will occur. When 
DSBs arise the more error-prone repair mechanism, NHEJ, which requires approximately 30 minutes to 
complete, takes precedence over HR to deal with the genetic stress. ccRCC develops when cells acquire more 
mutations and there is greater genomic instability which increases the metastatic potential of the cells. There 
may also be increased proteasomal activity, which leads to even lower Jade-1 levels and even less inhibition of 
NHEJ. C) If where there was small molecule developed that could stabilize Jade-1 in ccRCC, this would increase 
Jade-1 abundance and allow it to perform its renal tumor suppressor functions, including inhibiting NHEJ by 
negatively regulating DNA-PKcs. The cancer cells, which relied on this repair pathway, would be unable to 
repair quickly, and enlist HR, which takes approximately seven or more hours to complete. The cells would 
undergo apoptosis and the developing tumor would shrink. In general there would also be fewer mutations that 
would contribute to the cells metastatic capabilities in this situation. 
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